Inhibition of Essential Protein-Protein Interactions in Plasmodium and SARS-CoV-2 by Berliner, Zachary Hunter
 
 
INHIBITION OF ESSENTIAL PROTEIN-PROTEIN 
















A thesis submitted to Johns Hopkins University in conformity with the requirements for 



















© 2021 Zachary Berliner 





Malaria is caused by Plasmodium parasites. A critical step during merozoite entry 
into red blood cells (RBCs) is the formation of a tight junction between the parasite and 
RBC, as it commits the parasite for invasion. Interaction between two parasite proteins, 
AMA1 on the parasite surface and RON2 on the RBC, is critical for junction formation. A 
47-amino acid peptide in RON2 (RON2L) mediates this interaction. Our lab has shown 
that the RON2L peptide can act as a self-targeting inhibitor by competing to bind AMA1 
and preventing parasites from entering RBCs. 
 The goals of this study are to 1) evaluate half-life extension approaches by fusing 
RON2L with human IgG Fc and albumin binding domain (ABD035) and 2) optimize 
expression of an in silico designed AMA1-RON2 inhibitor (Pep12) and assess its 
biochemical and biological activity. We designed Fc and ABD035 fusion constructs of 
RON2L and Pep12, optimized protein expression and purification, and evaluated their 
activity. We describe methods for purifying the Pep12-Fc dimer and RON2L-ABD035. We 
show that RON2L-ABD035 binds albumin, and both constructs have high affinity for 
AMA1. Finally, we demonstrate that the Pep12-Fc fusion protein potently blocks 
parasite invasion of RBCs. Our results demonstrate the promise of AMA1-RON2 
inhibitors in preventing symptomatic malaria. We also show the potential viability of 





 The COVID-19 pandemic, caused by the virus SARS-CoV-2, is the most notable 
major public health event since the 1918 influenza pandemic. The virus uses the 
receptor binding domain (RBD) of its Spike protein to bind to human ACE2 to enter host 
cells. Here, we have expressed and purified both the RBD and full-length Spike proteins 
in HEK293T cells. We have developed an assay to specifically measure anti-RBD 
antibodies that block its binding to ACE2. We demonstrate a strong correlation between 
levels of such blocking antibodies and virus neutralization assay (NT). Evaluation of NT in 
convalescent plasma or after vaccination can be challenging, particularly in places not 
prepared to do such complex assays. We therefore present a relatively easy biochemical 
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Part I: Engineering an Inhibitor of an Essential 





A. Global Burden of Disease 
Malaria has afflicted humanity since antiquity. “Father of Medicine” Hippocrates 
(460 BCE – 370 BCE) and Ancient Greek philosopher Celsus (25 BCE – 54 CE) described in 
detail the periodic fevers associated with the disease.1 To this day, malaria is a major 
global public health issue. In 2015, the World Health Organization (WHO) published the 
Global Technical Strategy for Malaria 2016-2030 (GTS), with the stated goal to provide 
“a framework for the development of tailored programmes to accelerate progress 
towards malaria elimination.”2 This guide established milestones for reduction of global 
malaria mortality and incidence over 5-year periods until 2030, with an overall goal of 
reducing both by at least 90% and eliminating malaria in at least 35 countries.2 An 
analysis from the WHO in 2016 determined 21 countries that could reach the GTS 
milestone of malaria elimination in at least 10 countries by the year 2020, known as the 
E-2020 initiative; this list was based on the number of indigenous cases from 2000 to 
2015, the declared objectives from each country, and the judgment from WHO experts.3 
As of 2019, Paraguay and Algeria have been certified malaria free; China and El Salvador 
have made formal requests for certification; Iran, Malaysia, and Timor-Leste had no 
indigenous cases in 2018 and 2019 (though an outbreak in Timor-Leste in 2020 is being 
investigated); and Belize and Cabo Verde reported no indigenous cases for 2019.4 
Overall, there were approximately 229,000,000 cases of malaria globally in 2019, 
accounting for 409,000 deaths.4 By comparison, pandemic Coronavirus Disease 2019 
(COVID-19) has resulted in a cumulative total of 421,000 deaths in the United States of 
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America as of January 26, 2021.5 Unfortunately, both the malaria case incidence and 
deaths per population both fall short of the GTS milestones, by 37% and 22%, 
respectively.4 Clearly, much work needs to be done in order to meet the targeted 90% 
reductions by 2030. 
 
B. Parasite Life Cycle 
Malaria is caused by parasites of the genus Plasmodium and transmitted by 
female Anopheles mosquitoes.6,7 These parasites are members of the phylum 
Apicomplexa, which also includes Toxoplasma gondii (the etiological agent of 
toxoplasmosis) and Crytosporidium (the cause of cryptosporidiosis).8,9 Malaria affects a 
wide variety of vertebrates, from birds and scaled reptiles to mice and bats.10 Five 
species of Plasmodium are responsible for the disease in humans: Plasmodium 
falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and 
Plasmodium knowlesi.11 Of those species, P. falciparum is the deadliest, and, therefore, 
the most important one from a public health perspective.6 However, P. vivax is also a 
major concern.6 The Plasmodium life cycle is complex, spanning many different life 
stages and occurring in both the mosquito vector and the human host. Initially, when a 
female Anopheles mosquito infected with Plasmodium takes a bloodmeal, she injects 
parasites in the sporozoite stage into the human. Those injected sporozoites quickly 
move from the dermis, through the vasculature, and to the human liver, where they will 
invade hepatocytes. This entire process takes at least 30 minutes. Over the next 2 to 10 
days, the parasite will rapidly replicate inside the liver cell, resulting in the eventual 
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release of up to 40,000 merozoites upon lysis of the cell. In P. vivax and P. ovale, a single 
sporozoite can form a hypnozoite within a hepatocyte.11 Hypnozoites can remain 
dormant in the liver for months or years, complicating the treatment process of malaria 
caused by those two species.11 The merozoites released from the liver enter the 
bloodstream, beginning the asexual blood stage of the life cycle. This erythrocytic stage 
is responsible for symptomatic disease in malaria. In the blood stage, a merozoite will 
invade a red blood cell (either an erythrocyte or reticulocyte, depending on the 
species).6 Once the merozoite has entered the cell, it will transition to the next steps of 
its development. It will progress to the ring stage, followed by the trophozoite, before it 
becomes a schizont, containing 16 to 32 merozoites.7 The schizont will eventually burst, 
lysing the cell and releasing the merozoites into the bloodstream, where each of these 
daughters is able to invade another cell. One asexual cycle takes between 36 and 72 
hours, depending on the species.6 At some point, some merozoites will commit toward 
forming gametocytes inside the red blood cell instead of continuing the asexual cycle, 
and the gametocytes traffic toward the skin. When an uninfected female Anopheles 
mosquito bites and infected person, she will take up some of the gametocytes. Inside 
the mosquito’s midgut, the male microgamete will fuse with the female macrogamete, 
forming first a zygote, then an ookinete. The ookinete then migrates through the midgut 
epithelium and embeds itself on the tissue on the other side, on the edge of the 
hemocoel (body cavity). The ookinete transforms into an oocyst. Repeated cell divisions 
occur inside the oocyst, forming numerous sporozoites. The oocyst eventually bursts, 
releasing sporozoites into the mosquito body cavity. The sporozoites can invade many 
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mosquito tissues, causing a systemic infection. Some sporozoites cross into the salivary 
glands, where they can be injected into another human with a subsequent bloodmeal to 
infect another host. The life cycle is shown in Figure 1.6 
Figure 1. Plasmodium Life Cycle.6 
 
C. Malaria Drugs and Drug Resistance 
Malaria can be prevented, treated, and, in many cases, cured by a variety of 
pharmaceuticals. Some of those drugs include quinine (QN), chloroquine (CQ), 
piperaquine (PPQ), pyrimethamine (PYR), and artemisinin (ART).12 In the mid-1600s, 
Europeans became aware of the Cinchona tree from South America, whose bark could 
be used to treat fevers.13 In 1820, scientists derived quinine, the active antimalarial 
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component, from the bark.14 Bayer AG synthesized chloroquine from quinine in 1934, 
and chloroquine soon became the gold standard drug for treating and curing malaria.15 
As is expected when one drug or drug family is disproportionately used to treat a 
pathogen, resistance to chloroquine was first detected in 1959.15 By the late 1980s, 
resistance to chloroquine and other quinoline derivatives in Plasmodium falciparum, the 
parasite species responsible for the deadliest strain of malaria, had become 
widespread.15 In 1993, it was discovered that treatment in Malawi with chloroquine 
resulted in a 58% treatment failure rate, so Malawi stopped the use of the drug that 
year.16 The worldwide spread of chloroquine and pyrimethamine resistance is shown in 
Figure 2.17 CQ and PPQ (another quinoline) resistance is mediated by mutations in the 
Plasmodium falciparum transporter PfCRT, particularly the K76T mutation.18 These 
mutations lead to reduced uptake of the drug, allowing the parasites to survive longer.18 
Interestingly, the effectiveness of CQ against Plasmodium falciparum malaria was 
reassessed in Malawi 12 years after the nation stopped using the drug; a randomized 
study found a cumulative efficacy of 99% for chloroquine, with a worst-case efficacy of 
80% when assuming an unknown outcome was a treatment failure.19 This successful 
reintroduction is likely a result of the resistant strain containing some sort of fitness 
cost.20 The strategy of simply reintroducing chloroquine is not practical, as a resistant 
strain could arise that does not have the associated reduction in fitness.20  
Currently, the recommended first-line of treating malaria is with artemisinin-
based combination therapy (ACT), which involves the use of ART in combination with 
other, slower-acting drugs.4 In 2009, Dondorp et al. reported a dramatic increase in 
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parasite clearance time in patients from Pailin, Cambodia, compared to patients in 
Wang Pha, Thailand, after treatment with an artesunate-mefloquine ACT.21 The WHO 
recently defined artemisinin resistance as a delay in parasite clearance following 
treatment with artesunate monotherapy or with an ACT.22 From that initial detection by 
Dondorp et al., strains resistant to many other ACTs have also been found.17 As shown 
by the map in Figure 2, ART resistance has spread to multiple other countries in 
southeast Asia.17 Artemisinin resistance has been associated with polymorphisms in the 
kelch (K13)-propeller domain, though that phenotype appears to still be constrained to 
southeast Asia.22,23 As of 2019, southeast Asia has shown treatment failure rates of 
nearly 20% for artesunate-amodiaquine and artesunate-mefloquine, but the rest of the 
world does not seem to have significant ACT resistance yet.4 It is of utmost importance 
that artemisinin resistance not be allowed to spread to other areas, particularly to 
Africa. To prevent widespread ACT resistance, more therapies for the disease must be 
developed. 
Figure 2. Map of the Spread of Chloroquine, Pyrimethamine, and ACT Resistance.17 The heatmap 
indicates the areas with the highest percentage of people with detectable P. falciparum ABS (asexual 
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blood stage) parasites present in the blood. The black arrows depict the movement of chloroquine 
resistance, and the red arrows show the spread of pyrimethamine resistance. 
 
D. Malaria Vaccines 
Vaccines are an important component needed to reduce malaria globally. In 
August 2006, the WHO published the Malaria Vaccine Technology Roadmap, which put 
forth guidance for the research, development, and implementation of a malaria 
vaccine.24 Critically, this document established the goal to develop and license a first-
generation malaria vaccine by 2015 that has a protective efficacy of at least 50% against 
severe disease and death for longer than one year.24 The vaccine that is furthest along in 
development is the RTS,S/AS01 vaccine, developed by Glaxo Smith Kline (GSK) in 
collaboration with the Walter Reed Army Institute of Research.25 The primary malarial 
component of the vaccine consists of a repeat region, called NANP, of the P. falciparum 
circumsporozoite protein (CSP).25,26 The CSP is the protein that surrounds the sporozoite 
stage of the parasite, and the NANP repeats are highly immunodominant B cell 
epitopes.25 The CSP component in the RTS,S also includes three strong T cell epitopes to 
ensure a strong immune response against the parasite.25,26 Finally, the CSP is fused to 
the Hepatitis B Virus surface protein, which will assemble a virus-like particle (VLP) to 
serve as protein carriers.25,26 The AS01 is a novel liposome-based adjuvant made by GSK. 
The Phase III trial for the RTS,S vaccine began in March 2009 and concluded in January 
2014, the results of which were published in 2015.27 In infants 6-12 weeks old, the 
vaccine with booster reported an efficacy of 25.9% against clinical malaria and 17.3% 
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against severe malaria (the latter value was not statistically significant).27 In children 5-
17 months old, the vaccine with booster had a 36.3% efficacy against clinical malaria 
and 32.2% against severe disease.27 In infants, the half-life of the short-lived antibody 
response is 45 days and that of the long-lived antibody response is 634 days.28 Similarly, 
in children, the half-life of the short-lived response is also 45 days and that of the long-
lived response is 591 days.28 By comparison, the antibody half-lives for Tetanus, 
Varicella-Zoster Virus (the cause of chicken pox and shingles), and Measles are 11, 50, 
and 3014 years, respectively.29 Despite the vaccine falling short of the 50% goal set forth 
by the Malaria Vaccine Technology Roadmap, the European Medicines Agency’s 
Committee for Medicinal Products for Human Use (CHMP) “adopted a positive opinion 
in accordance with Article 58 of Regulation (EC) No 726/2004.”30 This determination 
indicated the vaccine for immunization in children from 6 weeks to 17 months.30 In light 
of the opinion from CHMP, the WHO issued an opinion on the vaccine.31 In this opinion, 
the WHO expressed concerns about the reproducibility of the protection offered to 
children 5-17 months old and was critical of the 4-dose schedule of the RTS,S vaccine.31 
To address these issues, the organization recommended a pilot implementation in 3-5 
countries in sub-Saharan Africa solely in the older age group.31 The WHO also 
established the study to address other potential negative health effects, like impact on 
all-cause mortality and the potential causal relationship of meningitis and cerebral 
malaria.31 The pilot study was initiated in 2019 in Malawi, Ghana, and Kenya, and the 
results are expected to be reviewed in 2021.4 Though there are many vaccines in 
development addressing various stages of the parasite life cycle, only three others have 
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moved to Phase II trials: the ChAd63/MVA ME-TRAP version of the RTS,S/AS01; 
GMZ2/Alhydrogel; and MSP3-LSP/AlOH.32 Though the RTS,S vaccine has finished its 
Phase III clinical trial, the WHO still had enough misgivings about it to trigger further 
studies; the vaccine’s efficacy falls short of the standard set by the WHO in 2006, and it 
seems that it does not produce long-lasting immunity.24,27,28,31 These shortcomings with 
RTS,S, combined with the dearth of viable vaccine alternatives, demonstrate the clear 
need for the development of more vaccines with higher efficacy.  
 
E. Merozoite Invasion 
The asexual blood stage of the parasite life cycle begins with merozoite (the 
invasive form) entry into red blood cells (RBCs). Several secretory organelles, all located 
at the apical end of the merozoite, are crucial for invasion: the rhoptries, the 
micronemes, and the dense granules (Figure 3).33 The rhoptries, which are a pair of tear-
shaped organelles, can be further divided into the rhoptry bulbs and the rhoptry 
necks.34 The process of invasion is a multi-step process, as shown in Figure 4.35-37 This 
description will particularly focus on P. falciparum. In the first step, the merozoite 
weakly interacts with the surface of the erythrocyte.35-37 Though the specific parasite 
proteins used in this step are not well-defined, it is possible that merozoite surface 
protein 1 (MSP1) is involved to some degree.7,35 Next, the parasite reorients so that the 
apical end is in contact with the red blood cell. This interaction, mediated by the Duffy 
binding-like proteins and the reticulocyte homology ligands (particularly PfRh5), is much 
stronger than the initial contact.35,36 The third step is the critical formation of the 
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moving junction. The rhoptry neck protein (RON) complex, including RON2, RON4, and 
RON5, is secreted from the rhoptry neck into the RBC; RON2, a transmembrane protein, 
inserts into its plasma membrane.34 Apical membrane antigen 1 (AMA1) is secreted 
from the micronemes onto the merozoite surface and interacts with RON2 on the RBC 
surface.36  AMA1 is also anchored to the actin-myosin motor located beneath the 
parasite membrane.38 After the formation of the tight junction by the binding of AMA1 
to RON2, the glideosome helps drive the actin-myosin motor to steadily move the 
parasite into a developing parasitophorous vacuole (PV) inside the RBC.35,38 The fifth and 
final stage of invasion is the resealing of the PV and cell membrane.35,36 At the 
conclusion of this step, the merozoite is completely encased in the PV within the 
targeted erythrocyte.35,36  
Figure 3. Illustration of a Merozoite and Its Major Organelles.33 The apical end is on the right side of 




Figure 4. Steps of Merozoite Invasion into a Red Blood Cell.37 Merozoite (Mrz) in blue; Red Blood Cell 
(RBC) in red. 
 
F. AMA1-RON2 Interaction 
Binding of AMA1 to RON2 is necessary for the formation of the moving junction 
and subsequent invasion of Plasmodium merozoites into erythrocytes.37,39 As discussed 
above, AMA1 is secreted onto the merozoite surface, while the RON2 protein is inserted 
into the plasma membrane of the RBC. This is a unique adaptation whereby the parasite 
provides both the receptor and ligand required for a critical step in invasion. AMA1 and 
RON2 are also both expressed in sporozoites.40,41 Through the use of the AMA1 inhibitor 
R1, Yang et al. (2016) determined that AMA1 is also highly important for invasion of 
sporozoites into liver cells.42 Knockdown of ron2 in sporozoites was also associated with 
reduced infection of mosquito salivary glands and invasion of hepatocytes.43 The AMA1-
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RON2 interaction, therefore, is incredibly important for three major invasion processes 
during the parasite life cycle. 
 
G. AMA1-RON2 as an Anti-Malarial Target 
Researchers have investigated multiple ways of inhibiting the interaction 
between AMA1 and RON2 to prevent parasite invasion into erythrocytes and 
hepatocytes. Broadly, inhibitors can be characterized as small molecule inhibitors or 
peptide inhibitors, based off the origins of the inhibitor. For small molecules, a screen of 
21,733 of them yielded 3 compounds that inhibited AMA1-RON2 complex formation 
and blocked merozoite invasion.44 Upon further optimization, 2 daughter molecules, 
NCGC00262650 and NCGC00262654, inhibited merozoite invasion across multiple 
strains of P. falciparum with “a 3- to 5-fold lower IC50” as compared to the parent 
compound.44  
Several peptide-based inhibitors have also been identified. In 2005, Harris et al. 
described R1, a peptide discovered by phage display that specifically targets AMA1.45 R1 
demonstrated strong dose-dependent inhibition of P. falciparum 3D7 and D10 strains.45 
However, R1 was shown to exclusively bind to AMA1 in only those two strains.45,46 
Though N-methylation of certain residues improves the association between R1 and the 
AMA1 of other P. falciparum strains, the strain-specificity of this peptide is a major 
barrier to its utility in a medical capacity.46 
Lamarque et al. (2012) and Tyler and Boothroyd (2011) identified a region 
conserved in Apicomplexa near the C-terminal end of RON2 that interacted with 
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AMA1.39,47 Srinivasan et al. (2011) and Vulliez-Le Normand et al. (2012) further 
characterized the region to a short, 47-amino acid peptide between two alpha-helices of 
RON2, a region termed “RON2L.”37,48,49 Critically, RON2L contains two highly-conserved 
cysteines, which form a disulfide bond essential for RON2L binding to AMA1.37 This 
peptide binds inside a hydrophobic groove of AMA1, as does R1.37,48 Previous studies by 
the lab have determined that exposure of the malaria parasites to the RON2L peptide or 
other small-molecule inhibitors of the AMA1-RON2 interaction can potently block 
merozoite invasion of red blood cells.37,44 Similarly, antibodies that block this AMA1-
RON2 interaction also block merozoite invasion.49,50 A study in mice showed that 
vaccination with an AMA1-RON2L complex can confer protection to mice against lethal 
challenge with the YM strain of P. yoelii, a species of mouse malaria.49 A follow-up 
vaccination study in Aotus monkeys found that the AMA1-RON2L complex protected 
against P. falciparum FVO strain parasite challenge.50 Recent studies in our lab 
conjugated RON2L to the heavy and light chain of a human IgG1 (2A10) that retained its 
ability to bind AMA1 and block merozoite invasion.51 This inhibitor was able to equally 
bind multiple strains of P. falciparum, as measured by ELISA.51 By GIA, the inhibitor 
exhibited dose-dependent inhibition against P. falciparum from the 3D7 strain.51 As 
shown by these various studies from our lab, RON2L is a potent inhibitor of merozoite 
invasion that functions by preventing the AMA1-RON2 interaction. 
 
H. Antibody-Mediated Immunity and Fc Fusion 
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The most conspicuous method by which antibodies can combat infection by 
intracellular pathogens is through the activity of neutralizing antibodies. In the case of 
the Plasmodium asexual blood stages, this method would feature antibodies binding to 
the surface of merozoites to prevent them from invading red blood cells.52 However, 
there are other mechanisms antibodies can use to protect against malaria. One study 
found that antibodies can fix complement component C1q to the merozoite, initiating 
the complement cascade to prevent invasion.53 This antibody-mediated complement-
dependent (Ab-C’) inhibition appears to be more commonly used than direct 
inhibition.53 A third mechanism features the “cooperation between antibodies and 
cells.”52 In Ab-dependent cellular inhibition (ADCI), blood monocytes recognize 
antibodies bound to merozoites using the Fc receptors FcγRIIa and FcγRIIIa and block 
the division of trophozoites.52,54,55 ADCI is independent from phagocytosis of opsonized 
pathogens.55 
Antibodies, particularly the Fc portions, are very advantageous for conjugation to 
pharmaceuticals. These conjugates are called Fc fusion proteins. The inclusion of the Fc 
domain allows the Fc fusion protein to trigger the complement fixation, ADCI, and 
phagocytosis described above.56 IgG1, IgG2, and IgG4 all have long half-lives due to 
recycling by the neonatal Fc receptor (FcRn).57 This recycling is also initiated by the Fc 
domain, so Fc fusion proteins can also be long-lived in the serum.56,57 The first Fc fusion 
protein, devised by Capon et al. in 1989, was designed to block HIV-1 infection of T cells 
by fusing the gp120-binding domain of CD4 to the Fc domain of IgG1.57,58 Enbrel® 
(etanercept), the first Fc fusion protein on the market, was approved in 1998 for 
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treatment of rheumatoid arthritis.57 Since then, many other Fc fusion proteins have 
been approved for marketing in the US, including Amevive® (alefacept) for psoriasis; 
Zaltrap® (ziv-aflibercept) for metastatic colorectal cancer; and Trulicity® (dulaglutide) for 
type 2 diabetes mellitus (T2DM).57 
 
I. Albumin and Albumin Fusion Proteins 
Albumin is the most abundant plasma protein in humans, with an average 
concentration of around 632µM.59 It is a single-chain polypeptide that is 585 amino 
acids long and 66.439kD in molecular weight.59,60 Human serum albumin (HSA) is an 
incredibly stable protein, with 17 disulfide bonds, and it is also a highly soluble protein 
that is very pH- and temperature-resistant.59 HSA’s unique biology means that it can 
bind a wide variety of ligands, from ions to carboxylates to fatty acids.59 The protein can 
also reach many different tissues, including accumulating in cancerous or inflamed 
regions, so it can transport molecules all throughout the body.60 Crucially, albumin is 
incredibly long lived as a result of FcRn recycling and its size, with an average half-life of 
19 days.57 This long half-life, along with its role as a molecular transporter, makes HSA 
an intriguing target for fusion to pharmaceuticals.57 In 1992, Yeh et al. created the first 
notable HSA conjugate, fusing albumin to CD4 to block HIV.61 They reported a 140-fold 
half-life increase as compared to soluble CD4.61 Since then, many other researchers 
have used HSA to extend the lives of their proteins, like Smith et al. (2001), who 
extended the half-life of their Fab by 7-fold.60,62 The first HSA fusion protein approved 
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for marketing was the T2DM drug albiglutide, known as Tanzeum® in the US and 
Eperzan® in the EU, though many others are on the market or in development.57 
 
J. Albumin-Binding Peptides 
One concern with fusion to the large albumin protein is the possibility of steric 
hinderance reducing the activity of the fusion protein.63 For example, in a 2011 study 
from Miyakawa et al., IFNγ fused to mouse serum albumin resulted in a 200-fold lower 
potency than un-modified IFNγ, despite the fusion protein lasting much longer in 
serum.64 Therefore, efforts have been made to use albumin-binding peptides (ABPs), 
small molecules or peptides that bind to albumin, instead of the full albumin protein.60 
In 2002, Dennis et al. used phage display to identify a number of ABPs, including SA21.65 
In a 2013 follow-up study, Miyakawa et al. fused an SA21 sequence to IFNγ instead of 
the HSA fusion. The fusion retained about 50% of the biological activity of IFNγ alone 
while lasting longer in the serum.66 Other ABPs have been developed based on bacterial 
albumin-binding proteins that help camouflage the bacteria from the immune system.67 
For instance, streptococcal protein G (SPG) is a bacterial protein that can bind both 
albumin and immunoglobulins through a 15 residue ABD.67 ABD035, an albumin binding 
peptide derived from SPG, was developed based on its stability and high affinity to 
HSA.68 ABD035 exhibited an affinity for HSA with KD of 500fM, a 2400-fold improvement 
compared to G148-ABD, the native SPG peptide.68 A study published in 2014 by Levy et 
al. that compared the effects of SA21 and ABD035 as fusion partners for the drug 
exenatide resulted in long circulation times in rats and non-human primates.69,70 Both 
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conjugates showed activity in mice 24 hours after glucose challenge, and both 
significantly reduced HbA1c, body weight, and food intake in diabetic mice over 4 
weeks.69 Based on the results of this study, both SA21 and ABD035 were able to 
dramatically extend the activity of exenatide, with ABD035 lasting longer than SA21 in 
circulation of non-human primates.69 Other studies have also demonstrated that fusion 
of various therapeutics to ABD035 result in drastically increased half-lives.71-74 
 
K. Summary 
Here, we designed peptide-based inhibitors of the AMA1-RON2 interaction and 
evaluated their potential as a novel antimalarial strategy. We also tested these 
inhibitors using two different approaches, namely as a fusion protein with a human IgG1 
Fc or a small albumin-binding peptide (ABD035). These were tested with the eventual 
goal of improving inhibitor stability and enhancing retention in vivo. We also used an in 
silico approach to design a more potent inhibitor (Pep12) based on the structure of 
RON2L and conducted proof-of-concept studies to test expression, folding, and 
biochemical and neutralizing activity. The goal of this study is to develop a novel 
antimalarial approach by self-targeting the parasites, using its own trick against itself. 
Such AMA1-RON2 inhibitors are expected to be strain-transcendent and, therefore, are 





Materials and Methods 
Plasmid Design and Cloning 
Plasmid Design 
 A total of four different plasmids were designed. The first, Pep12-Fc-pcDNA3.1, 
includes the Pep12 peptide and the Fc portion of the heavy chain of human IgG1, with 
the Pep12 upstream of the Fc (Figure 5A). Two other plasmids utilize the SA21ABP 
peptide. SA21ABP-PfRON2L-pcDNA3.1 Nterm (Figure 5B) has the SA21ABP located 
upstream of the PfRON2L peptide, while PfRON2L- SA21ABP-pcDNA3.1 Cterm (Figure 
5C) has the SA21ABP downstream of PfRON2L. The sequence for SA21ABP was taken 
directly from Dennis et al. (2002).65 A fourth construct, PfRON2L-ABD035-pcDNA3.1, 
includes ABD035 in place of SA21ABP, and the albumin binding domain is downstream 
of PfRON2L (Figure 5D). The sequence used is the one noted in Jonsson et al. (2008).68 
Each of those four plasmids included a signal sequence at the N-terminal end of the 
protein sequence so that the proteins will be secreted by the cell along the secretory 
pathway. It has been found that small variations in the signal sequence can significantly 
alter the degree of protein secretion.75 Each plasmid also featured a (Gly-Gly-Gly-Gly-
Ser)3 motif as a linker between the RON2L or Pep12 and the fusion partner (Fc, 
SA21ABP, or ABD035). The purpose of the linker is to connect the components of the 
constructs without compromising the function of the individual proteins.76,77 
Specifically, the (G4S)3 linker we selected has been used to produce functional 
proteins.78 All albumin-binding constructs contained a 6x histidine tag for the purposes 
of purification using nickel resin. The backbone of each plasmid was the pcDNA™3.1 
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plasmid from Invitrogen (Cat. #V79020/V79520). This plasmid contains a 
cytomegalovirus (CMV) enhancer-promoter for high-level expression and a bovine 
growth hormone (BGH) polyadenylation signal and transcription termination sequence 
for enhanced mRNA stability.79  
Figure 5. Plasmid Maps. Maps of (A) Pep12-Fc-pcDNA3.1 (B) SA21ABP-PfRON2L-pcDNA3.1 Nterm, (C) 
PfRON2L-SA21ABP-pcDNA3.1 Cterm, and (D) PfRON2L-ABD035-pcDNA3.1. 
 
Digestion, Gel Extraction, and Gibson Assembly 
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 DNA fragments coding for Pep12 and RON2L were synthesized (IDT Biologika) 
and cloned by Gibson Assembly into linearized pcDNA3.1, resulting in Pep12-Fc, 
SA21ABP-PfRON2L (ABP-Nterm), PfRON2L-SA21ABP (ABP-Cterm), and PfRON2L-ABD035 
(RON2L-ABD035). All synthetic CAN fragments contained a 20 base pair overhang 
necessary for the Gibson Assembly procedure.80,81  
 For the Gibson Assembly, the NEBuilder HiFi DNA Assembly Protocol from New 
England BioLabs was followed.82,83 Briefly, 50ng of the vector (the double-digested 
backbone) was mixed with the insert at a 1:2 vector to insert ratio and ligated using 
NEBuilder HiFi DNA Assembly Master Mix (New England BioLabs, Cat. #E2621) at 50.0˚C 
for 60 minutes.  
  
Transformation into E. coli, Verification of Insert by Colony PCR, and Plasmid Preparation 
 The plasmids were transformed into XL-10 Gold® Ultracompetent Cells (Agilent 
Technologies, Cat. #200314) or DH5α cells and selected on Amp+ LB agar plates. 
Multiple colonies were picked off of the transformation plate and used for colony PCR. 
Briefly, a mixture for each colony in a PCR reaction contained 2µL of OneTaq Polymerase 
Buffer 5x (NEB, Cat. #B9022S), 0.2µL of 10mM dNTP, 0.05µL of OneTaq Polymerase 
(NEB, Cat. #M0480L), 0.2μL each of the pcDNA3.1 Seq. Fwd. and PcDNA3.1 Seq. Rvs. 
primers (see Appendix A for primer sequences), and 7.35µL of MiliQ water. PCR 
products were verified by agarose gel electrophoresis. Each colony that was determined 
to contain the plasmid of choice was cultured in LB Broth containing 100µg/mL 
ampicillin overnight in an incubator-shaker set to 37˚C and 225rpm. Plasmids were 
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purified on a ZymoPURE™ Plasmid Miniprep or Midiprep Kit (Zymo Research, Cat. 
#D4209 or Cat. #D4201).84,85 The concentrations of the purified plasmids were measured 
on a NanoDrop® 1000 Spectrophotometer. The final amino acid sequences of Pep12-Fc 
and RON2L-ABD035 are shown in Appendix B. 
 
Protein Production 
HEK293T Cell Transfection 
 Human Embryonic Kidney 293T cells (HEK293T) cells were cultured using 
DMEM/High Glucose (HyClone, Cat. #SH30243.01) containing 10% Fetal Bovine Serum 
(FBS) (Gibco, Cat. #26140-079) and 1% Penicillin Streptomycin (Gibco, Cat. #15140). The 
cells were maintained in vented tissue culture flasks at 5% CO2 at 37˚C. Cells were 
passaged to new flasks when they reached 70-80% confluency. Once the cells were 
passaged approximately 20 times, frozen cells stored in 90% DMEM and 10% DMSO 
were thawed and subsequently maintained. 
 For transfections, the jetPRIME transfection procedure was followed.86 
Transfections were performed in flasks at 70-80% confluency. About 2 hours prior to 
transfection, the media of the flask was replaced with new media. For Pep12-Fc 
transfections, the media was replaced with 10% Ultra Low IgG Fetal Bovine Serum 
(VWR, Cat. #10018-826). For a 5mL transfection, 10µg of plasmid was diluted in 332µL 
of jetPRIME Buffer (Polyplus, Cat. #712-60). 10µL of jetPRIME Reagent (Polyplus, Cat. 
#114-15) was added to the diluted mixture, tapped and vortexed to mix, and spun 
down. The mixture was allowed to sit at room temperature for 10 minutes before 
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adding to culture flasks. The supernatant was collected 2-3 days later and centrifuged at 
4,000rpm for 3 minutes to remove debris. Eventually, the procedure was optimized to 
use 1mg/mL polyethylenimine (PEI) instead of the jetPRIME Reagent. The PEI was made 
following a protocol from Cold Spring Harbor.87 In a 5mL transfection (with 10µg of 
DNA), 40µL of PEI was used. Any larger transfections were scaled up proportionately. 
 
Expi293F Cell Transfection 
 Since one of the components of the DMEM media used for maintenance and 
transfection of HEK293T cells is FBS, albumin will be present in the cell supernatant. 
Considering that the ABP-Cterm, ABP-Nterm, and RON2L-ABD035 constructs are 
designed to bind albumin, the presence of albumin in the supernatant could render 
purification and analysis of those constructs difficult. We selected the Expi293™ 
Expression System from Gibco, which uses Expi293F™ cells (Gibco, Cat. #A14527), a 
high-yield transient expression system based on suspension-adapted HEK293 cells.88 
Therefore, the Expi293™ Expression System from Gibco, using Expi293F™ cells (Gibco, 
Cat. #A14527) and serum-free, protein-free Expi293™ Expression Medium (Gibco, Cat. 
#A14351-01), was used for protein expression. The Expi293™ Expression Medium 
(Gibco, Cat. #A14351-01) is serum-free and does not contain albumin.88 Additionally, 
this expression system yields 2-10 times more protein than other expression systems.88 
The cells were maintained in PETG vented shaker flasks in the Expi293™ Expression 
Medium at 8% CO2 and 37˚C with a relative humidity of 90% on a shaker set to 100rpm. 
When the cells reached a density of around 3-5 x 106 live cells/mL, they were passaged 
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to a density of 0.4 x 106 live cells/mL. The cells were counted using a hemocytometer or 
a Countess™ II FL Automated Cell Counter from Life Technologies after the cells were 
stained with Trypan Blue Stain (Lonza, Cat. #17-942E). 
 On the day of transfection, the cells were diluted to a density of 3 x 106 viable 
cells/mL. For a 10mL transfection, 10µg of plasmid was diluted in 600µL of Opti-Plex™ 
Complexation Buffer (Gibco, A40968-01). 32µL of ExpiFectamine™ 293 Reagent (Gibco, 
Cat. #A14524) was diluted in 520µL of Opti-Plex™ Complexation Buffer and allowed to 
sit for 5 minutes. The diluted ExpiFectamine™ 293 Reagent was added to the diluted 
plasmid, mixed, and incubated at room temperature for 10-20 minutes. This 
complexation mixture was slowly added to the flask, and the flask was replaced in the 
incubator-shaker. Between 18- and 22-hours post-transfection, 60µL of ExpiFectamine™ 
Transfection Enhancer 1 (Gibco, Cat. #A14524) was added to 600µL of ExpiFectamine™ 
Transfection Enhancer 2 (Gibco, Cat. #A14524). We optimized the collection day, so the 
supernatant was collected on day 4 post-transfection. The supernatant was then 
centrifuged at 4,000rpm for 10 minutes, filtered through a 0.22µm filter, and stored at -
80˚C.  
 
SDS-PAGE to Confirm Protein Expression 
 Proteins secreted in the supernatants were initially evaluated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions and 




ELISA to Confirm Expression of Pep12-Fc 
 To determine if the Pep12-Fc protein was expressed in both the HEK293T and 
Expi293™ cells, enzyme-linked immunosorbent assays (ELISAs) were performed. For 
each ELISA, a 96-well plate was coated with 1µg/mL Goat x-Human IgG-Fc Fragment 
Affinity Purified (Bethyl, Cat. #A80-104A) diluted in 1x PBS and allowed to sit overnight 
at 4˚C. The following day, ELISA Blocking Buffer (1x PBS, 0.1% Tween 20, and 1% BSA) 
was added to each well and incubated for 1 hour at room temperature. For the 
standard, Human Reference Serum (Bethyl, Cat. #R510-110) was added to ELISA 
Blocking Buffer to reach a concentration of 1.98µg/mL. The standard and protein 
samples were diluted four-fold down the plate, and each sample was run in duplicate. 
After 1 hour incubation at room temperature, the plate was washed 3 times with Wash 
Buffer (1x PBS and 0.1% Tween 20), followed by incubation for 1 hour with Goat Anti-
Human IgG (H+L), Mse/Bvn/Hrs SP ads-HRP (Southern Biotech, Cat. #2016-05) diluted at 
1:10000. Following a wash step, each well was incubated with BioFX TMB Super 
Sensitive One Component HRP Microwell Substrate (Surmodics, Cat. #TMBS-0100-01) 
for 2 minutes. The reaction was quenched with an equal volume of either TMB Stop 
Reagent, 450nm (Bioworld, Cat. #21530071-1) or BioFX 450nm Liquid Stop Solution for 
TMB Microwell Substrates (Surmodics, Cat. #LSTP-1000-01). The plate was read at 
450nm-650nm using a microplate reader, and concentrations were calculated based off 
the interpolated standard curve in GraphPad Prism. 
 
His-Tag Pulldown to Check Expression of ABP-Cterm, ABP-Nterm, and RON2L-ABD035 
26 
 
 Because ABP-Cterm, ABP-Nterm, and RON2L-ABD035 all had 6x histidine tags, 
pull-downs could be performed using HisPur™ Ni-NTA Resin (Thermo, Cat. #88221). 
ABP-Nterm, ABP-Cterm, or RON2L-ABD035 supernatants were incubated with the beads 
overnight at 4˚C. The next day, the samples were washed 5 times with 25mM imidazole 
in 20mM sodium phosphate buffer pH 7.4, 300mM NaCl (25mM IBB). After the final 
wash, the beads were centrifuged for 5 minutes at 10,000rpm. The bead pellets were 
resuspended in 10µL of 1x PBS and boiled with LDS Sample Buffer (Novex, Cat. #B0007) 
and Sample Reducing Agent (Novex, Cat. #B0009). The samples were spun for 5 minutes 
at 10,000rpm and the supernatants were run on SDS-PAGE. 
 To confirm the results of the SDS-PAGE gel, a western blot was performed. 
Following the transfer of the proteins to a 0.2µm PVDF membrane, the membrane was 
incubated with Western Blocking Buffer (1x TBS, 0.1% Tween 20, 2% skim milk) for one 
hour on an orbital shaker. 6x-His Tag Monoclonal Antibody (Invitrogen, Cat. #MA1-
21315) was diluted 1:500 in Western Blocking Buffer, and the membrane was incubated 
with the antibody on a rocker overnight at 4˚C. The next day, the membrane was 
washed 3 times with Wash Buffer (1x TBS, 0.1% Tween 20) for 5 minutes each and 
incubated with secondary antibody made of HRP-Goat Anti-Mouse IgG (H+L) (Invitrogen, 
Cat. #62-6520) secondary antibody diluted 1:1000 in blocking buffer for 1 hour. After 
the membrane was washed another 3 times, it was incubated for 5 minutes with 
SuperSignal™ West Pico PLUS Chemiluminescent Substrate (Thermo, Cat. #34578) and 





Ammonium Sulfate Precipitation 
 Initially, an ammonium sulfate (AS) precipitation method was evaluated to purify 
the Pep12-Fc fusion protein. A test was set up to determine the ideal percentages of AS 
to use to purify Pep12-Fc.89 As shown in Figure 6, 10mL of supernatant was mixed with a 
particular volume of Saturated Ammonium Sulfate Solution (Teknova, Cat. #A2030) to 
reach the desired percent saturation. The solutions were incubated on ice for 1 hour 
and centrifuged at 10,000rpm and 4˚C for 30 minutes. The supernatants were mixed 
with the next volume of AS to increase the percent saturation by 10% and allowed to 
incubate for another hour on ice. Meanwhile, the pellets were dissolved in 1mM PMSF 
in 1x PBS. The mixture with a 10% increase in AS was then spun for 30 minutes at 
10,000rpm and 4˚C. The resulting pellet was also resuspended in 1mM PMSF in 1x PBS. 
All of the resuspended pellets, along with the final supernatant, were stored at -80˚C to 
be tested by ELISA to determine purification efficiency (as described above). 
Once the ideal percentages had been selected (25% AS to remove contaminants 
followed by 55% AS to precipitate Pep12-Fc), the protein precipitate was dissolved in 




Figure 6. Schematic of AS Purification Test.89 The initial supernatant was brought to a percent saturation 
with ammonium sulfate (AS). After the mixture was incubated and spun down, the remaining supernatant 
had its AS saturation increased by 10%. That mixture was also spun down. The first pellet, second pellet, 
and remaining supernatant were all tested by ELISA to determine the most effective percentage of AS to 
use to purify the Pep12-Fc Protein. Image adapted from Burgess (2009).89 
 
Protein A Purification of Pep12-Fc 
 Staphylococcal Protein A, also known as Protein A, is commonly used for 
purification of antibodies because of the ability of Protein A to bind to IgG.90 This 
approach was used to purify the Pep12 protein, as it contains an Fc fusion. The protein 
was purified on a Bio-Rad NGC Quest 10 Chromatography System using a Bio-Scale™ 
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Mini Affi-Prep® Protein A Cartridge (Bio-Rad, Cat. #732-4600). First, an equal volume of 
Protein G IgG Binding Buffer (Thermo, Cat. #21011) was added to the Pep12-Fc 
supernatant. For Equilibration, 10mL of IgG Binding Buffer was pumped through the 
system. Sample Application was done using a sample pump. The column was then 
washed with 15mL of IgG Binding Buffer. Protein was eluted in five 2mL volumes of IgG 
Elution Buffer (Thermo, Cat. #21009) and neutralized immediately with 60µL of TrisCl pH 
9.5. The entire method was done with a flow rate of 0.4mL/min. The purification was 
visualized on a chromatogram detecting absorbance at 280nm. 
 
IMAC Purification of ABD05 
 Immobilized-metal affinity chromatography (IMAC) is purification based on the 
idea that metal ions, like Ni2+ and Cu2+, can bind histidine and cysteine.91 Since the 
RON2L-ABD035 protein contained a His tag, the protein could be purified on an IMAC 
column on the NGC Quest 10 Chromatography System using the Bio-Scale™ Mini Nuvia™ 
IMAC Ni-Charged column (Bio-Rad, Cat. #780-0811). Unless otherwise noted, the 
method was conducted at 7mL/min. The column was equilibrated with 25mM Imidazole 
in 20mM Sodium Phosphate Buffer pH 7.4, 300mM NaCl (25mM IBB), and the sample 
was applied through a sample pump at a flow rate of 1mL/min. Equilibration was done 
with 15mL of 25mM Imidazole Binding Buffer. Sample Application occurred through the 
sample pump at a flow rate of 1mL/min. A Wash step occurred with 15mL of 25mM 
Imidazole Binding Buffer. The Elutions were performed at a flow rate of 3mL/min. The 
column was then washed with 5 column volumes (CV) of 25mM IBB. Since we previously 
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determined that the ABD elutes around 300mM imidazole, we used the following 
Elution pattern: two steps of 2mL elutions with 100mM imidazole; two steps of 2mL 
elutions with 300mM imidazole; and three steps of 2mL elutions with 500mM imidazole. 
The final Wash used 30mL of 25mM Imidazole Binding Buffer, with the first 6mL of the 
wash also collected in 2mL fractions. The other wash step, along with the flow-through 
from sample application, was collected as well. 
 
CHT Purification of Pep12-Fc 
 To attempt to separate the Pep12-Fc oligomers by size and just isolate the 
dimeric form, the Pep12-Fc protein was purified using CHT Ceramic Hydroxyapatite. CHT 
is a mixed-mode medium that can be used to purify a variety of proteins, from 
antibodies to viruses.92 The column used was the Bio-Scale Mini Cartridge, CHT Type II, 
40µm Media (Bio-Rad, Cat. #7324332), and the purification was done on the NGC Quest 
10 Chromatography System. The Protein A-purified Pep12-Fc was first concentrated on 
an Amicon® Ultra-4 10kD Centrifugal Filter (Milipore, Cat. #UFC801096), and the buffer 
was exchanged from 1x PBS to 10mM NaPO4, 100mM NaCl, pH 6.5 (the running buffer 
for the CHT purification method). The method was in accordance with 3.3.11 Scouting 
Protocol IB: IgG from Bio-Rad, with the exception that there was no Ca2+ 
supplementation.93 The entire method was run with a flow rate of 6.2mL/min. The 
column was first Pre-Equilibrated with 3CV of 500mM NaPO4, pH 6.5. Next, the column 
was Equilibrated in 10mM NaPO4, 100mM NaCl, pH 6.5. About 100µL of the Pep12-Fc 
protein was injected into the sample loop during the Equilibration step, and 1mL of the 
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running buffer was run through the sample loop for Sample Application. Next, the 
column was washed with 5CV of running buffer. Elution was done with 20CV of elution 
buffer on a linear gradient, starting from 10mM NaPO4, 100mM NaCl, pH 6.5, 15mM 
MES and ending with 10mM NaPO4, 2mM NaCl, pH 6.5, 15mM MES (the gradient was 
the molarity of NaCl in the solution). Each fraction collected contained 4.5mL of elute. 
Finally, the column was Washed with 1CV of 10mM NaPO4, 100mM NaCl, pH 7.5. This 
method was also performed using two other running buffers, with the 10mM NaPO4 
replaced with 40mM NaPO4 and with 80mM NaPO4. 
 
Size Exclusion Chromatography of Pep12-Fc 
 To attempt to separate the Pep12-Fc oligomers by size and just isolate the 
dimeric form, the Pep12-Fc protein was purified by Size Exclusion Chromatography 
(SEC). The Protein A-purified Pep12-Fc was first concentrated on an Amicon® Ultra-4 
10kD Centrifugal Filter to a concentration of around 7mg/mL, as measured by a 
NanoDrop® 1000 Spectrophotometer. The SEC was performed on an ENrich™ SEC 650 
10 x 300 Column (Bio-Rad, Cat. #780-1650) on the NGC Quest 10 Chromatography 
System. The method was performed at a flow rate of 0.75mL/min. The Equilibration had 
1.25CV of de-gassed 1x PBS passed through the column. 200-240µL of Pep12-Fc was 
injected into the sample loop during the Equilibration step. During the Sample 
Application step, 4mL of 1x PBS was passed through the sample loop. The protein was 




SDS-PAGE and Western Blot to Confirm Protein Purification 
 For both the Pep12-Fc and RON2L-ABD035 proteins, SDS-PAGE was used to 
confirm that the protein was purified and to identify which collections contained the 
proteins. For Pep12-Fc, gels were run under both reducing and non-reducing conditions. 
The gels for RON2L-ABD035 were solely run under reducing conditions. For non-
reducing gels, the volume of reducing agent was replaced with an equal volume of MiliQ 
water.  
The gel was transferred to a 0.2µm PVDF membrane for western blotting. For 
Pep12-Fc, the Mixed Range MW program (25V, 1.3A) was run for 9 minutes. For ABD, 
the Low MW program (25V, 1.3A) was run for 5 minutes. The membrane was then 
incubated for at least 30 minutes on an orbital shaker with Western Blocking Buffer 
composed of 1x TBS, 0.1% Tween 20, and 2% skim milk. Goat anti-Human IgG (H+L)-HRP 
diluted to 1:10000 was used to detect Pep12-Fc. The ABD primary antibody was 6x-His 
Tag Monoclonal Antibody (Invitrogen, Cat. #MA1-21315) diluted to 1:500 and HRP-Goat 
Anti-Mouse (H+L) (1:1000 dilution) secondary antibody were used to detect RON2L-
ABD035. Finally, the blots were incubated for 5 minutes with SuperSignal™ West Pico 




ELISA to Determine Pep12-Fc Sample Concentrations 
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 ELISAs were performed for Pep12-Fc samples from various fractions/collections 
from the many different purifications to determine the concentrations of protein. Either 
96-well plates or half-area 96-well plates were used in these experiments. These ELISAs 
were performed in the same manner as those described in ELISA to Confirm Expression 
of Pep12-Fc, except the protein was first diluted 1:1000 in blocking buffer before the 
two- or four-fold dilutions down the plate. The concentrations of each sample tested 
were extrapolated from the generated standard curve. 
 
ELISA to Test Binding of Pep12-Fc to AMA1 
 ELISAs were conducted to assess the ability of Pep12-Fc collections and 
oligomers to bind AMA1. This experiment was also done in either a normal 96-well plate 
or a half-area 96-well plate. The wells were coated with 1µg/mL of AMA1 isolated from 
the P. falciparum strain 3D7. Some wells were coated with 1µg/mL of Goat x-Human 
IgG-Fc Fragment Affinity Purified for the purpose of a loading control. Pep12-Fc samples 
being tested were diluted to 1:100 in ELISA Blocking Buffer, then diluted 2-fold going 
down columns in duplicate. A standard could not be used, as no standard would bind 
directly to the AMA1. The rest of the procedure was identical to the one described 
previously. IC50 values were calculated using the known concentrations that had been 
calculated from the Fc-coated ELISAs. 
 
ELISA to Test RON2L-ABD035 Binding to AMA1 
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 ELISAs were performed to ensure that the RON2L-ABD035 construct, which 
included RON2L, could still bind to AMA1 from the 3D7 strain of P. falciparum. These 
ELISAs were done in half-area 96-well plates. This ELISA underwent numerous 
optimization steps in the coating solution, blocking buffer, concentration of AMA1, and 
concentrations of primary and secondary antibodies. In preparation for this ELISA, the 
concentrations of ABD samples were determined using the Qubit™ Protein Assay Kit 
(Invitrogen, Cat. #Q33211) on a Qubit™ Fluorometer. The plate was coated with 2µg/mL 
of RON2L-ABD035 and stored at 4˚C. The next day, ELISA Milk Blocking Buffer (1x PBS, 
0.1% Tween 20, 1% skim milk) was added to the plate and incubated for 1 hour. Milk 
was used as a component of the blocking buffer because of the ABD protein’s ability to 
bind to albumin. The starting dilution of AMA1 was optimized to 0.5µg/mL in ELISA Milk 
Blocking Buffer. AMA1 was diluted 2-fold down duplicate columns, and the dilutions 
were added to the plate to incubate for 1 hour. The dilution of the primary antibody, 
anti-AMA1 previously isolated from mice, was optimized to 1:1000 (3µg/mL). Once the 
plate was washed 3 times with Wash Buffer, the anti-AMA1 was added to the plate and 
incubated for an hour. The optimized dilution of 1:2500 secondary antibody was 
prepared using HRP-Goat Anti-Mouse IgG (H+L) (Invitrogen, Cat. #62-6520) in ELISA Milk 
Blocking Buffer. After 3 washes with Wash Buffer, the wells received the secondary 
antibody and were let sit. An hour later, the plate was once again washed 3 times. Room 
temperature BioFX TMB Super Sensitive One Component HRP Microwell Substrate was 
added, incubated for 2 minutes, and the reaction was then stopped using an equal 
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volume of TMB Stop Reagent, 450nm or BioFX 450nm Liquid Stop Solution for TMB 
Microwell Substrates. The plate was read at 450nm-650nm. 
 
ELISA to Test RON2L-ABD035 Binding to Albumin 
 The ability of RON2L-ABD035 to bind to different mammalian species’ albumins 
was analyzed. The albumin proteins tested were bovine, human, and mouse. This ELISA, 
done in a half-area 96-well plate, was optimized for the blocking buffer, the dilutions of 
ABD, and the dilutions of the primary and secondary antibodies. Since all three albumin 
variants were tested simultaneously, each species’ albumin was applied to duplicate 
columns. Each albumin was coated at a concentration of 2µg/mL. The plate was stored 
at 4˚C overnight. The next day, the plate was incubated with ELISA Milk Blocking Buffer 
(1x PBS, 0.1% Tween 20, 1% skim milk) for 1 hour. The RON2L-ABD035 was diluted to 
2µg/mL in ELISA Milk Blocking Buffer, with subsequent 3-fold dilutions down the 
columns of the plate. 1 hour later, the plate was washed 3 times with Wash Buffer (1x 
PBS, 0.1% Tween 20), then 1:1000 6x-His Tag Monoclonal Antibody (Invitrogen, Cat. 
#MA1-21315) in ELISA Milk Blocking Buffer was added to each well. After another hour, 
the plate was again washed 3 times, and 1:5000 HRP-Goat Anti-Mouse IgG (H+L) was 
added and let sit for one hour. Once the plate was washed another 3 times, room 
temperature BioFX TMB Super Sensitive One Component HRP Microwell Substrate was 
incubated in each well for 2 minutes. The reaction was stopped with an equal volume of 
TMB Stop Reagent, 450nm or BioFX 450nm Liquid Stop Solution for TMB Microwell 




RON2L-ABD035 Sandwich ELISA 
 A sandwich ELISA for RON2L-ABD035, testing the ability of the protein to bind 
albumin and AMA1 simultaneously, was performed. Like with the ELISA to Test ABD 
Binding to Albumin, the half-area 96-well plate was coated with 2µg/mL of bovine, 
human, and mouse albumin. Each albumin occupied two columns in duplicate. After the 
coated plate was stored overnight at 4˚C, ELISA Milk Blocking Buffer (1x PBS, 0.1% 
Tween 20, 1% skim milk) was added to each well and allowed to sit for 1 hour. The 
RON2L-ABD035 underwent 3-fold dilutions down each column, beginning with a 
concentration of 2µg/mL. Then, AMA1 from P. falciparum 3D7 was diluted to 1µg/mL 
and added to every well. After 1 hour, a 1:1000 dilution (3µg/mL) of anti-AMA1 
previously isolated from mice was prepared and added to each well. Next, 1:2500 HRP-
Goat Anti-Mouse IgG (H+L) was added for an additional hour. The plate was washed 3 
more times, and BioFX TMB Super Sensitive One Component HRP Microwell Substrate 
was added to each well. 2 minutes later, the reaction was quenched with an equal 
volume of TMB Stop Reagent, 450nm or BioFX 450nm Liquid Stop Solution for TMB 
Microwell Substrates. The plate was read at 450nm and 650nm, and those optical 
densities were subtracted. 
 
Gel Shift Assay 
 The binding of the RON2L-ABD035 protein to its ligands, AMA1 and albumin, was 
visualized by gel shift assays. ABD was mixed with AMA1 at multiple different molar 
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ratios. In one experiment, the molar ratio of RON2L-ABD035 and AMA1 was 1:1. In 
another experiment, the number of moles of the ABD fusion varied, while the number 
of moles of the binding partners remained constant. Moles of RON2L-ABD035 was 
based off the expected molar mass of 12,102.69g/mol. After the proteins were 
incubated together for 30 minutes at room temperature, the mixtures were placed on 
ice. For a control for AMA1 binding, AMA1 was also mixed at a 1:1 molar ratio with the 
RON2L peptide. All of the mixtures were brought up to equal volumes. 
 The samples were then prepared for native gel electrophoresis using the 
NativePAGE™ Novex® Bis-Tris Gel System.94 The 1x NativePAGE™ Anode Buffer was 
made by diluting the NativePAGE™ 20x Running Buffer (Invitrogen, Cat. #BN2001) in 
MiliQ water, and the 1x NativePAGE™ Dark Blue Cathode Buffer was made by diluting 
the NativePAGE™ 20x Running Buffer and the NativePAGE™ 20x Cathode Buffer Additive 
(Invitrogen, Cat. #BN2002) in MiliQ water. Each sample had enough NativePAGE™ 4x 
Sample Buffer (Invitrogen, Cat. #BN20032) added to reach 1x. 1µL of NativePAGE™ 5% 
G-250 Sample Additive (Invitrogen, Cat. #BN2004) was added for every 10µL of total 
volume. Each tube was brought up to the desired volume using MiliQ water. Each well 
of the NativePAGE™ 4-16% Bis-Tris Gel (Invitrogen, Cat. #BN2111BX10) was washed 3 
times with 10µL of 1x NativePAGE™ Dark Blue Cathode Buffer. 10µL of that buffer was 
added to each well prior to the samples being loaded. The 1x NativePAGE™ Anode 
Buffer was added to the back of the gel tank, while the 1x NativePAGE™ Dark Blue 
Cathode Buffer was added to the front. The gel was run for 80 minutes at 120V and 
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400mA. The gel was then destained using a solution composed of 50% methanol, 40% 
water, and 10% glacial acetic acid. It was visualized on a Syngene G:Box imager. 
 In some cases, the gel was used for a western blot instead of being immediately 
destained. The gel was transferred to a 0.2µm PVDF membrane and incubated with a 
1:500 dilution of anti-His primary antibody. 1:1000 HRP-Goat Anti-Mouse IgG (H+L) 
(Invitrogen, Cat. #62-6520) was used as the secondary antibody. The blot was incubated 
for 5 minutes with SuperSignal™ West Pico PLUS Chemiluminescent Substrate (Thermo, 
Cat. #34578). The blot was visualized on a Syngene G:Box imager. 
 
GIA 
 In preparation for Growth Invasion Assays (GIAs), the proteins first needed to 
have their buffers exchanged into incomplete RPMI (KD Medical, Cat. #CUS-0645). Each 
sample was concentrated in an Amicon® Ultra-4 10kD Centrifugal Filter (Milipore, Cat. 
#UFC801096) that was pre-wet with 1x PBS. The incomplete RPMI was next mixed with 
the concentrated protein and spun down at 4000rpm and 4˚C; this step was performed 
a total of 3 times. The sample, now in iCM, was passed through an Ultrafree®-MC 
0.22µm GV Durapore® Centrifugal Filter Unit (Millipore, Cat. #UFC30GV0S) and 
aliquoted into multiple tubes. The concentration of each Pep12-Fc sample was 
calculated by ELISA using the procedure detailed in ELISA to Determine Pep12-Fc Sample 
Concentrations. The concentration of each ABD sample was calculated using the Qubit™ 
Protein Assay Kit (Invitrogen, Cat. #Q33211) on a Qubit™ Fluorometer. The desired 
concentration for every sample was 10mg/mL. 
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 For the GIA, infected RBCs at 0.5% parasitemia (schizonts) and 4% hematocrit 
were incubated with the proteins in a final volume of 40µL for 72 hours at 37˚C. Cells 
were collected at the end of the 72 hours and lysed in the presence of Thiazole Green 
(SYBR® Green I) (Biotium, Cat. #40086) for 30 minutes at room temperature to stain the 
parasite DNA. The plates were read with excitation and emission spectra around 480nm 
and 520nm, respectively. The results were blank subtracted and normalized with 
















Identification of Pep12, a Potent AMA1-RON2 Inhibitor 
 One peptide that will be used extensively is an enhanced version of RON2L 
known as Pep12. Pep12 was designed in collaboration with Dr. Gabriel Rocklin of 
Northwestern University and Dr. David Baker of the University of Washington. The 
schematic for the generation of Pep12 is shown in Figure 7. First, the crystal structure of 
the predicted interaction between RON2L and the hydrophobic pocket of AMA1 was 
analyzed, and the RON2L residues essential for interaction with AMA1 were identified. 
Those critical residues, which comprise a hairpin loop, became integral for the de novo 
generation of any protein designed to bind in the same location of AMA1. Fragments 
listed in PlasmoDB were assembled onto a backbone that also included the essential 
RON2L hairpin using “a Rosetta Monte Carlo-based fragment assembly protocol” (Figure 
7A).95 A library of potential AMA1 inhibitors were selected and tested for their ability to 
bind AMA1 using a yeast surface display approach.96 Briefly, yeast cells displaying 
various designs on their surface were incubated with varying concentrations of 
fluorescently-labeled AMA1 proteins. Proteins binding to AMA1 Cells were then sorted 
by flow cytometry and identified for sequencing. Through iterative screening, peptides 
that had the strongest affinities were selected. The selected peptides were next 
evaluated for their ability to bind to a different allele of AMA1 to identify those that 
bind in a strain-transcendent manner. The designs were also tested for proteolytic and 
thermal stability using a similar method. The proteins were tagged with a c-Myc tag and 
labeled with a fluorescent antibody. Proteolytic cleavage resulted in the loss of the tag 
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and the attached fluorescent antibody, so exposure to increasing concentrations of 
proteases resulted in selection for the most stable peptides. This screening process is 
shown in Figure 7B.  
Ultimately, Pep12 demonstrated the strongest affinity for AMA1 while still 
maintaining high proteolytic and thermal stability, so it was selected for further 
evaluation. Pep12 demonstrated inhibitory activity against parasite invasion, as 
demonstrated by GIA (Figure 7C). The Pep12 peptide exhibited an IC50 of 45nM, a 10-
fold greater inhibition compared to RON2L.  
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Figure 7. Process of Screening for Inhibitor Pep12. (A) In silico derivation of the peptide library. 
Based on the structure of the interaction between RON2L and AMA1, the critical RON2L residues were 
identified. Backbones using fragments from PDB and RON2L amino acids essential for binding AMA1 were 
assembled. (B) Chemical and biological screening of peptide library. The library of peptides was displayed 
on yeast and iteratively selected for the ability to bind AMA1 tightly. Similar yeast display experiments 
were used to test for proteolytic and thermal stability. The structures of the peptides were predicted. (C) 
GIA data of one peptide, Pep12, compared to RON2L. Based on this 10-fold greater inhibition, we have 
chosen to further test Pep12’s function and ability to block AMA1 from binding Pep12. The 
crystallographic image of AMA1 and RON2L is from Vulliez-Le Normand et al. (2012).48 The image of the 
yeast display experiment is adapted from Rocklin et al. (2017).96 
 
HEK293T Expression of Pep12-Fc 
 Once the Pep12-Fc was successfully inserted into the pcDNA3.1 plasmid and 
sequence verified, the completed plasmid was transfected into HEK293T cells to 
produce protein. Pep12-Fc expression was monitored by ELISA and quantified using a 
human reference IgG standard curve (Figure 8A). RON2L-Fc was used as a positive 
control. Based on the calculated concentrations, we concluded that Pep12-Fc was being 
expressed in HEK293T cells (Figure 8B). Next, we evaluated the ability of Pep12-Fc to 
bind to AMA1, its intended target. RON2L-Fc was used as a positive control. This ELISA 
demonstrated that both RON2L-Fc and Pep12-Fc bound to AMA1 as expected (Figure 
8C). Interestingly, while the amount of Pep12-Fc used was higher than RON2L-Fc (Figure 
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8B), its binding activity to AMA1 was lower than that of RON2L-Fc (Figure 8C), 
suggesting that not all Pep12-Fc expressed may be fully active. 
Figure 8. Expression of Pep12-Fc in HEK293T Cells. (A) Graph of a typical ELISA standard curve using 
Human Reference IgG. (B) The concentration Pep12-Fc expressed in HEK293T cells is shown in comparison 
to that of RON2L-Fc. (C) Qualitative comparison of RON2L-Fc and Pep12-Fc binding to AMA1 at the same 
dilutions used in 8B. 
 
Ammonium Sulfate Precipitation of Pep12-Fc 
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 The ammonium sulfate (AS) precipitation method, based on the principle that 
different proteins precipitate at different percentages of AS saturation, was used to 
preferentially precipitate and purify Pep12-Fc from other proteins in the culture media. 
This approach is widely used to separate IgG in culture media.89 Contaminants can be 
removed by first using a lower AS saturation, followed by a higher AS concentration that 
should yield most of the target protein.89 To find the ideal AS concentrations, a test 
purification like the one diagrammed in Figure 6 was set up. The starting AS percentages 
were 20%, 30%, 40%, 50%, and 60%. The resulting pellet was termed Precipitate 1. After 
that first round of purification, each sample had its AS saturation increased by 10%. The 
resulting pellet was called Precipitate 2. Based on the idea that 90% of a given protein 
can be precipitated with a 10% increase in AS saturation, the majority of the Pep12-Fc 
protein was expected to be located in Precipitate 2. The Supernatant is what remained 
after the second precipitation. Figure 9A shows the concentration of Pep12-Fc present 
in each precipitate and supernatant, as calculated by ELISA. A negligible amount of 
Pep12-Fc precipitated at below 30% AS, so 25% is an ideal percentage to remove 
contaminants without removing the target protein. 50% and 60% AS both contained 
very high concentrations of Pep12-Fc. Thus, 55% is sufficient to use for future 
purifications.  
 Precipitation may force proteins to misfold. We therefore performed an ELISA to 
confirm that Pep12-Fc could still bind its target. Even at the 50% and 60% AS, the most 
stressful of the environments, the precipitated Pep12-Fc could still bind AMA1 as 
effectively as the non-precipitated counterparts (Figure 9B). Ammonium sulfate 
45 
 
precipitation starting with 25% AS and followed with 55%, is a viable method for 
purifying functional Pep12-Fc protein.  
Figure 9. Ammonium Sulfate [(NH4)2SO4] Precipitation of Pep12-Fc. (A) Concentration of Pep12-Fc in 
each pellet and supernatant from the AS precipitation test. (B) ELISA data showing the AMA1 binding of 
the 50% and 60% AS pellets, each at 1:10 dilutions, compared to the binding of undiluted, non-
precipitated supernatant. 
 
Expi293™ Expression of Pep12-Fc 
 The low yields of protein in HEK293T prompted us to evaluate the Expi™293 
suspension cells that are optimized to produce high levels of recombinant antibodies. 
This system does not require any serum- or animal-origin proteins. 88 We wanted to see 
if the new cell line would yield more protein than the old line, and we also wanted to 
determine on which day post transfection to collect the Expi293™ supernatant to 
maximize protein expression. Supernatants from Expi cells were collected every day for 
5 days and compared with supernatant collected on day 4 from HEK293T cells, and 
Pep12-Fc was quantified by ELISA (Figure 10). While the HEK293T cells, which were 
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collected on day 4 post-transfection, produced Pep12-Fc at a concentration of 
1.86µg/mL, even Day 2 post-transfection in Expi293 cells produced 15 times more 
protein. When accounting for volume, Day 5 in Expi293 produced 3.75mg of protein 
compared to 18.6µg in HEK293T, a greater than 200-fold increase in total protein.  
Figure 10. Pep12-Fc Protein Expression in Mammalian Cells. Concentrations of Pep12-Fc protein 
produced in either HEK293T on day 4 or Expi293™ cells on days 2 to 5.  
 
Pep12-Fc Oligomerization 
 Once enough Pep12-Fc protein supernatant had been retrieved from Expi293™ 
cell cultures, individual batches of supernatant were purified on a Protein A column. 
Additionally, supernatant from HEK293T cells was precipitated by AS precipitation, then 
purified on the Protein A column. A typical chromatogram at 280nm resulting from a 
Protein A purification is shown in Figure 11A. For each purification, it was clear that the 
vast majority of the Pep12-Fc protein was located in Collections A/2 and A/3. The 
purified samples from Expi293 cells were run on SDS-PAGE under reducing and non-
reducing conditions. The Pep12-Fc construct was expected to dimerize through the Fc 
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region. We compared the proteins expressed in both HEK293T and Expi293 cells (Figure 
11B). The expected size of a Pep12-Fc monomer is around 32.5kD. In the reduced 
portion (left side) of the gel, the monomer is present in each sample. The dimer is 
expected to be around 65kD. Though the dimer is visible under non-reducing conditions 
(right side), higher molecular weight oligomers are seen in both. Based on the molecular 
weights of those other bands, we hypothesized that the Pep12-Fc protein was forming 
other oligomers in addition to the dimer and that oligomerization was not due to higher 
protein expression in Expi cells. 
Figure 11. Pep12-Fc Oligomerization. (A) Typical 280nm chromatogram of Pep12-Fc Protein A 
purification. (B) Gel of Protein A-purified Pep12-Fc protein from Expi293 and HEK293T cells. The standard 
used was SeeBlue® Plus2 Prestained Standard (Invitrogen, Cat. #LC5925). 
 
Pep12-Fc Oligomerization: A Function of Time? 
We questioned if oligomerization was a result of the protein sitting in the 
supernatant for multiple days. If the oligomers form while the protein is sitting outside 
the cell, we could simply collect the supernatant sooner and avoid this issue. We took 
samples of supernatant from an Expi293™ transfection on each day leading up to 
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collection on Day 4. Each sample was tested by non-reducing SDS-PAGE. Days 2, 3, and 4 
all show the same pattern of oligomers, suggesting that the oligomers likely form at the 
time of protein secretion in the supernatant (Figure 12). Even in Day 2, where there is 
comparatively little expression, the protein still oligomerizes. Based on this result, it 
appears that the Pep12-Fc monomers may aggregate inside the cell prior to exocytosis. 
Figure 12. Pep12-Fc Over Time. Unreduced gel of supernatant samples from each day post-transfection in 
Expi293™ cells. The standard used was SeeBlue® Plus2 Prestained Standard. 
 
Can Pep12-Fc Dimers be Separated from Oligomers?  
 We hypothesized that the form of Pep12-Fc may influence its ability to bind 
AMA1, thereby affecting its neutralizing activity. To test this hypothesis, it was 
necessary to separate the dimer from the oligomers. We tested this by size exclusion 
chromatography (SEC) to separate the protein forms based on size. The appearance of 
individual peaks, though they overlapped, indicated that the protein aggregates are 
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separating based on size (Figure 13A). The reduced SDS-PAGE gel illustrates that most of 
the protein coming out is Pep12-Fc, and the lower molecular weight bands may be 
fragments of the protein (Figure 13B). The non-reduced SDS-PAGE gel showed that 
fraction 14 and 15 contained higher proportions of the dimer compared to the 
oligomers (Figure 13C). However, SEC was not able to completely separate the dimers.  
Next, we attempted to isolate the dimer using a Ceramic Hydroxyapatite (CHT) 
column. The CHT column separates protein based off differential binding affinity for the 
resin based on net charge.92 However, analysis of the fractions by SDS-PAGE showed 
that this did not improve separation of the dimer and oligomers (Figures 13D and 13E). 
A western blot using anti-Fc antibodies confirmed that the higher molecular weight 
proteins are indeed Pep12-Fc oligomers (Figure 13F). 
These results point to SEC as a better approach to enrich the Pep12-Fc dimers. 
Therefore, we optimized the purification conditions (flow rate, amount of protein 
loaded, and collection volumes) to further improve protein separation (Figure 13G). This 
optimized SEC resulted in much improved separation of the dimer, as seen by a well-







Figure 13. Separation of Pep12-Fc Dimers and Oligomers. (A) An A280 chromatogram from an SEC 
purification of Protein A-purified Pep12-Fc. Many collections from that purification were run on SDS-PAGE 
under reducing (B) and non-reducing (C) conditions. (D) Chromatogram resulting from a CHT purification 
of Protein A-purified Pep12-Fc. The dark diagonal line illustrates that the Elution step featured a linear 
increase in concentration of NaCl. (E) Samples from the CHT purification run on a gel under reducing and 
non-reducing conditions. (F) Western blot with reduced and unreduced sides demonstrating the presence 
of Pep12-Fc oligomers after multiple methods of protein purification. (G) Chromatogram at 280nm 
showing the successful separation of the dimer from the other oligomers by SEC. The red arrow points to 
A/8, the fraction that almost exclusively contains the dimer. (H) Unreduced gel of collections from the 
successful SEC purification. The standard used in each gel and blot was SeeBlue Plus2 Prestained 
Standard. 
 
Pep12-Fc AMA1 Binding Activity—The Effect of Oligomerization 
Next, we tested if the form of Pep12-Fc (dimer vs. oligomer) affected its ability to 
bind its target AMA1. An ELISA was performed to compare the Protein A-purified Pep12-
Fc, which is comprised of a mixture of dimer and oligomers, and different fractions from 
SEC (fraction A/8, the Pep12-Fc dimer; and fractions A/5 and A/6, oligomers). Our 
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results indicate that the Pep12-Fc dimer binds AMA1 better than the oligomers (Figure 
14).  
Figure 14. Pep12-Fc Binding to AMA1. Binding curves for AMA1 binding to various Pep12-Fc oligomeric 
fractions or a mix of all oligomers (Protein A-Purified).  
 
Pep12-Fc Inhibition of P. falciparum Parasite Invasion 
 A growth invasion assay (GIA) was done with P. falciparum 3D7 to compare the 
neutralizing activities of Pep12-Fc and compare its activity to RON2L-Fc. Due to 
insufficient amount of purified dimer available for this assay, we used Protein-A purified 
Pep12-Fc that contains both dimer and oligomers. Our results show that the IC50 of 
Pep12-Fc was twice that of RON2L-Fc (Figure 15). Interestingly, when synthetic peptides 
corresponding to Pep12 or RON2L were used, a 10-fold higher potency for Pep12 was 
observed (Figure 7C). However, our ELISA results comparing activity of the different 
forms of Pep12-Fc indicated that the dimer is likely the active form (Figure 14). Since 
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only a small proportion of the Protein A-purified Pep12-Fc contains the dimeric form, 
this may be reflected in the neutralization assay. Future studies will evaluate methods to 
improve production and separation of the Pep12-Fc dimer and test its neutralizing 
activity against parasites. 
Figure 15. GIA data for Pep12-Fc Inhibition of P. falciparum. The corresponding IC50 value is shown in 
brackets. 
 
Expi293™ Expression of SA21ABP-Nterm, SA21ABP-Cterm, and RON2L-ABD035 
 As described in Section J of the Introduction, researchers have developed and 
refined peptides that bind to albumin. The peptide SA21 was derived from phage display 
by Dennis et al. (2002); when used as a fusion peptide, it has extended the half-lives of 
pharmaceuticals without diminishing their functions.65,66,69 Likewise, Jonsson et al. 
(2008) introduced ABD035, a peptide generated from Streptococcal protein G, which 
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has also demonstrated half-life extension as a fusion peptide.68,69,71-74 We designed 
constructs that fuse the RON2L peptide to SA21 or ABD035 (plasmid maps in Figure 5). 
As mentioned previously, the albumin-binding designs of the SA21ABP-Nterm, 
SA21ABP-Cterm, and RON2L-ABD035 constructs required expression in media that did 
not contain albumin. First, each plasmid was transfected in the Expi293™ Expression 
System. Unlike Pep12-Fc, these constructs only possessed a His tag. Since, the AMA1 
protein we used also had a His tag, we devised another method for detecting 
expression, using HisPur™ Ni-NTA Resin to pull down the desired proteins. The boiled 
beads were then analyzed by SDS-PAGE under reducing conditions (Figure 16A). To 
confirm the gel results, a western blot was done from a second pull-down (Figure 16B). 
The expected sizes of ABP-Nterm, ABP-Cterm, and RON2L-ABD035 are around 8.9kD, 
9.1kD, and 12.0kD, respectively. From Figure 16, it is clear that RON2L-ABD035 was 
pulled down and, therefore, is being produced. Conversely, ABP-Nterm and ABP-Cterm 
were not pulled down, so it is unknown whether they are being expressed. We 




Figure 16. Expression of Albumin-Binding Constructs in Expi293™ Cells. Gel (A) and western blot (B) 
showing the presence of RON2L-ABD035 from the pull-downs but a lack of ABP-Cterm and ABP-Nterm. 
The expected sizes of ABP-Nterm, ABP-Cterm, and RON2L-ABD035 are around 8.9kD, 9.1kD, and 12.0kD, 
respectively. The standard used was SeeBlue® Plus2 Prestained Standard. 
 
ABD Purification  
 Using the principle of metal ions binding to histidine tags, we tried to purify the 
ABD construct using HisPur™ Ni-NTA Resin.91 Two separate elutions with 300mM 
imidazole were loaded onto a reducing gel alongside the flow-through, boiled beads, 
and original supernatant (Figure 17). Virtually all of the protein present in the 
supernatant bound to the beads, as evidenced by the lack of the 12kD protein in the 
Flow-through, and most of the protein eluted off the beads, shown by the boiled beads. 
Purification on an immobilized-metal affinity chromatography (IMAC) column yielded 
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very similar results. Both purification methods were effective in primarily isolating the 
ABD protein.  
Figure 17. RON2L-ABD035 Purification. Reduced gel of a hand-purification of RON2L-ABD035 using Ni2+ 
beads. The beads were eluted twice, once with 100µL of 300mM imidazole and once with 200µL of 
300mM imidazole. The remaining beads were boiled and loaded onto the gel. 
 
RON2L-ABD035 Binding to Serum Albumin 
The RON2L-ABD035 protein is composed of two components: a RON2L peptide 
designed to bind AMA1 and the ABD035 domain for binding albumin. We first assessed 
the ability of RON2L-ABD035 to bind to albumin. Previous research with albumin binding 
peptides has shown that the same peptide can exhibit differential binding strengths to 
different species of albumin.97 Therefore, we assessed three types of albumin for our 
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tests by ELISA: bovine, human, and mouse. RON2L-ABD05 bound MSA and HSA but not 
to BSA (Figure 18). 
Figure 18. RON2L-ABD035 Binding to Albumin. ELISA showing binding of RON2L-ABD035 to albumin from 
different species. 
 
RON2L-ABD035 Binding AMA1 
Next, we assessed the binding of RON2L-ABD035 to AMA1 by ELISA. Our data 
demonstrates that RON2L-ABD035 binds to AMA1 in a dose-dependent manner (Figure 
19A). Combined with the earlier results, our data indicates that the RON2L-ABD035 
fusion protein associates with albumin through the ABD domain while successfully 
interacting with its parasite target AMA1. 
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We also assessed the RON2L-ABD035 binding to AMA1 by a native PAGE gel shift 
assay. When AMA1 was mixed with RON2L-ABD035 at a 1:1 molar ratio, a second, 
slightly higher molecular weight band is visible when compared to AMA1 run alone 
(Figure 19B).  
Figure 19. RON2L-ABD035 Binding to AMA1. (A) ELISA binding curve of the binding of P. falciparum 3D7 
AMA1 to RON2L-ABD035. (B) Native gel following the gel shift assay of RON2L-ABD035 mixed with AMA1. 
1:1 Mix is the mixture of 1mol RON2L-ABD035 and 1mol AMA1. The red arrow points to the higher 
molecular weight band, indicating the association of the construct with AMA1. The RON2L-ABD035 and 
AMA1 wells were each loaded with 1mol of the respective protein. The standard used was NativeMark™ 
Unstained Protein Standard (Thermo, Cat. #LC0725). 
 
RON2L-ABD035 Binding AMA1 and Albumin Simultaneously  
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A crucial aspect of this protein’s effectiveness is its ability to simultaneously bind 
albumin and AMA1. The protein must bind its parasite target, but albumin binding is 
critical for the half-life extension. To ensure that albumin binding does not severely 
diminish the ability to bind AMA1, we performed a sandwich ELISA. Briefly, this ELISA 
had a 2µg/mL coating of each albumin species. Once the plate was incubated with a 
spectrum of RON2L-ABD035 concentrations, the plate was exposed to 2µg/mL of AMA1. 
Protein was detected using 1:1000 of an anti-AMA1 antibody, followed by 1:2500 anti-
mouse. The subsequent binding curves are shown in Figure 20. These curves show that 
RON2L-ABD035 is able to bind AMA1 while concurrently binding to MSA or HSA.  
Figure 20. RON2L-ABD035 Binding AMA1 and Albumin Simultaneously. Binding curves of sandwich ELISA 






Malaria is an ancient disease that has long been an incredible source of burden 
for people across the globe. The disease’s historical burden is evident from the various 
mutations in the human genome that confer resistance to P. falciparum malaria, 
including abnormal hemoglobin traits (hemoglobinopathies) like Hemoglobin S—the 
mutation responsible for the sickle cell trait—and β-thalassemia.98,99 Malaria has been 
so deadly that these mutations continue to persist, despite the numerous health defects 
they bring.100 The global burden of malaria is not just an artefact of history, however. A 
comprehensive analysis of data from the Global Burden of Diseases, Injuries, and Risk 
Factors Study found that malaria was responsible for 45,000,000 disability adjusted life 
years (DALYs) in 2017.101 In 2017, malaria comprised 6.5% of all DALYs resulting from all 
communicable diseases and 1.8% of all DALYs from all causes across 195 countries.101 
Malaria is particularly a problem in low-income countries, where it was the sixth leading 
cause of death in 2019.102 The combination of this high public health burden, the lack of 
a long-term efficacious vaccine, and emerging drug resistance illustrates the need for 
better alternative therapeutics and vaccine candidates. 
 Here, we have devised two novel inhibitors of the parasite AMA1-RON2 
interaction that is crucial for merozoite invasion into erythrocytes. The first, RON2L, is a 
small peptide derived from a region of the RON2 protein that binds to the hydrophobic 
pocket of AMA1.37,48,49 The other is Pep12, a de novo-designed inhibitor based on 
creation derived from the RON2L structure. The Pep12 peptide was fused to the Fc 
region of human IgG1, while the RON2L was linked to ABD035, an albumin binding 
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domain first characterized by Jonsson et al. (2008).68 We wanted to compare the 
inhibitory activities of RON2L and Pep12, which was selected for a stronger affinity to 
AMA1. We chose conjugation to Fc to encourage antibody-mediated complement-
dependent inhibition, Ab-dependent cellular inhibition, and phagocytosis in addition to 
the Pep12 peptide inhibiting cellular entry by competitive binding to AMA1. Both Fc and 
ABD035 were also used as conjugates to extend the half-life of our construct in serum. 
We wanted to assess the effects of the two fusion partners on inhibitor activity. 
 We have demonstrated that our Pep12-Fc fusion can be expressed in HEK293T 
adherent cells and that those expressed proteins can bind to AMA1. We have also 
shown that the protein can be more expressed at a 75-fold higher concentration in the 
Expi293™ Expression System from Gibco. We showed that Pep12-Fc could be separated 
from other supernatant proteins by both ammonium sulfate and Protein A purifications. 
This protein is modeled after IgG antibodies, which form dimers in vivo. We found that 
the Pep12-Fc protein forms many different oligomers in addition to dimers, presumably 
through intermolecular interactions. The Pep12-Fc dimer was hypothesized to be the 
most active form of the protein, with the best ability to bind AMA1 and inhibit parasite 
invasion. The dimer proved incredibly difficult to separate from the other oligomers. 
Protein A purification only separated other proteins from the mix of Pep12-Fc 
oligomers, and the Ceramic Hydroxyapatite (CHT) column also proved unfit to separate 
the forms. Ultimately, Size Exclusion Chromatography (SEC) was able to separate the 
various oligomers. GIA showed that the mix of Pep12-Fc oligomers did not enhance 
neutralization compared to RON2L-Fc, compared to what was observed with the 
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corresponding synthetic peptides. Using an ELISA, we showed that the dimer is clearly 
able to bind AMA1 more effectively than the other oligomers individually and the mix of 
all the oligomers, possibly explaining the lack of enhancement in neutralizing activity 
when using a predominantly oligomeric form of Pep12-Fc.  
 Because the RON2L-ABD035035 protein binds albumin, HEK293T cells were not a 
viable option for expression of that protein. Instead, we demonstrated that the RON2L-
ABD035 conjugate could be expressed in the Expi293™ Expression System. Additionally, 
the presence of a histidine tag allows the protein to bind to Ni2+. We showed that the 
protein could be purified using either immobilized-metal affinity chromatography 
(IMAC) or Ni2+ beads. Through both a gel shift assay and an ELISA, we have shown that 
this RON2L fusion protein can bind to AMA1, its intended target. By ELISA, we found 
that RON2L-ABD035 can bind to the albumin proteins of mice, humans, and rats. 
Crucially, we found via sandwich ELISA that the RON2L-ABD035 protein can 
simultaneously bind albumin (from human, mouse, or rat) and AMA1, a critical aspect of 
the combination protein’s effectiveness (conferred by the RON2L peptide) and longevity 
(resulting from the ABD035 binding to albumin). 
  
Future Directions 
The purification of the Pep12-Fc protein is critical for its viability as a potential 
drug or vaccine. Though the first stage of purification in this study was mostly done on a 
Protein A column, the slow flow rate necessary for the Protein A column renders it 
impractical to use for large-scale purifications. For those larger purifications, our 
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optimized ammonium sulfate purification is much more favorable. The most challenging 
aspect of the purification, however, is the effective separation of the dimer from the 
rest of the oligomers that form. While the RON2L contains 2 cysteines, which form a 
single disulfide bond, the Pep12 peptide has 4 cysteines. These cysteines may be linking 
various Pep12-Fc peptides together, or they may interfere with the disulfide bond in the 
hinge region that joins two IgG monomers together. Since such a small proportion of the 
secreted protein is in the dimeric form, it would also be prudent to find a way to convert 
the various oligomers into the dimer. Attempts to remove any remaining dimer using 
sequential purification with an Amicon® Ultra-15 100kD Centrifugal Filter Unit 
(Millipore, Cat. #UFC910024) followed by an Amicon® Ultra-15 30kD Centrifugal Filter 
Unit (Millipore, Cat. #UFC903024) were unsuccessful (data not shown). It will likely be 
necessary to separate the bonds holding the oligomers together and re-form them. 
However, before going through the rigorous process of resolving the oligomerization 
issue, the various Pep12-Fc fractions should be tested alongside the dimer by GIA to 
confirm that the dimer has superior inhibitory ability. 
GIA data is needed to verify that Pep12-Fc, especially as a dimer, and RON2L-
ABD035 effectively block parasite invasion. Moreover, other strains of P. falciparum 
aside from 3D7 should also be tested by GIA. An inhibitor with cross-strain activity is 
critical for any drug or vaccine candidate. The Pep12-Fc dimer should have lower IC50 
values than Dr. Deepti Sarkar’s RON2L-Fc conjugates, since the Pep12-Fc is supposed to 
be an enhanced version of Pep12-Fc. For RON2L-ABD035, it would also be useful to 
perform surface plasmon resonance with different species’ albumin proteins to 
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generate dissociation constants. Once sufficient GIA data has been obtained, both 
constructs should have their inhibitors replaced with an analogous inhibitor of P. yoelii, 
a species of mouse malaria. From there, those mouse-adapted constructs will be dosed 
in mice to measure the longevity of the constructs in serum. For a control, other mice 
will be dosed with just the PyRON2L peptide. Once the constructs’ time in serum has 
been determined, they will be assessed for their ability to prevent symptomatic disease 
in a mouse malaria challenge. While those studies are being conducted, the constructs 
should be tested for the ability to bind sporozoites and inhibit sporozoite invasion into 
hepatocytes. The ultimate goal for these constructs is for them to show promise as 






Part II: Evaluating a Surrogate Assay to Measure the 






L. Global Burden of COVID-19 
 On December 30, 2019, ProMED reported the circulation of an “urgent notice on 
the treatment of pneumonia of unknown cause” coming out of the city of Wuhan in the 
Hubei province of the People’s Republic of China.103 The next day, the WHO’s Country 
Office in China learned of these cases of “viral pneumonia.”104 Later analysis found that 
the earliest reported symptom onset occurred on December 1, 2019.105 On January 9, 
2020, the WHO reported that the outbreak was caused by a novel coronavirus that was 
termed 2019-nCoV shortly thereafter.104 That January, researchers from the Wuhan 
Institute of Virology found that 2019-nCoV shared a 79.6% sequence homology with 
SARS-CoV BJ01, an isolate of the virus responsible for the severe acute respiratory 
syndrome (SARS) outbreak in 2003.106,107 From this result, the authors concluded that 
2019-nCoV was a part of the SARSr-CoV species of betacoronaviruses.106 Furthermore, 
additional analysis found 96.2% sequence identity to BatCoV RaTG13, a coronavirus that 
infects bats.106 Though the origins of the virus are unclear, it very likely entered the 
human population from an as yet unidentified animal reservoir.108 Further molecular 
analysis has found that the virus is related to ones that circulate in bats and 
pangolins.109 The Coronavirus Study Group of the International Committee on Taxonomy 
of Viruses named the novel coronavirus SARS-CoV-2 on February 11.110 
 The first death from SARS-CoV-2 was documented in China on January 11, 2020. 
According to the WHO’s first Novel Coronavirus (2019-nCoV) Situation Report, published 
on January 21, a total of 6 deaths had been reported in Wuhan City.111 The 282 total 
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confirmed cases were spread across four countries: China, Japan, Thailand, and the 
Republic of Korea. The first person in the United States diagnosed with the disease was 
formally diagnosed by the Centers for Disease Control and Prevention (CDC) on January 
20.112 Notably, a later analysis of serology samples found many samples collected prior 
to January 20 that were reactogenic to SARS-CoV-2, suggesting that the virus may have 
been introduced to the United States as early as December 13, 2019.113 Per the WHO’s 
eight Situation Report, published on January 28, the number of confirmed cases had 
ballooned to 4,593 across 15 countries, including Australia, France, and Germany along 
with the ones previously mentioned.114 106 deaths had occurred in China.114 In a speech 
on February 11, Dr. Tedros Adhanom Ghebreyesus, the Director-General of the WHO, 
named the new disease COVID-19.115 By that point, 393 cases and 1 death had been 
reported across 24 countries (excluding China); China had reported 42,708 cases and 
1,017 deaths.115 Exactly one month later, on March 11, Dr. Ghebreyesus declared 
COVID-19 as a pandemic.116 At the time of that declaration, COVID-19 had accounted for 
a total of 118,000 cases and 4,291 deaths across 114 countries.116 This pandemic still 
rages over one year later. According to the widget from the Johns Hopkins Coronavirus 
Resource Center, there have been 122,631,601 cumulative cases and 2,705,724 deaths 
across 192 countries as of March 20, 2021.117 The United States leads the world in cases, 
with 29,780,301 in total, and deaths, with 541,738.117  
 
M. Convalescent Plasma 
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 Serum therapy, “the administration of immune serum for the treatment of 
infections,” was first discovered for the treatment of diphtheria in 1890.118 
Subsequently, serum therapy was used for a variety of infectious diseases, including 
tetanus, measles, and mumps, up until the 1940s.118,119 Furthermore, convalescent 
plasma has also been used in several major public health events, like the 1918 influenza 
pandemic and the 2009-2010 H1N1 influenza pandemic.120 Based on this precedent, 
Casadevall and Pirofski proposed the administration of COVID-19 convalescent sera for 
means of prophylaxis and treatment of disease in March 2020.120 Its use, they argued, 
would be particularly beneficial in light of the lack of effective treatments or vaccines for 
COVID-19.120 
 In June 2020, Li et al. published the results of the first randomized clinical trial 
involving the use of COVID-19 convalescent plasma (CCP).121,122 Within 28 days, the 
patients who received CCP did not improve any faster than those who did not,  and 
there was also no significant difference in 28-day mortality or in “time from 
randomization to death” or randomization to discharge.122,123 The study only used 103 
participants, instead of the intended 200, so the statistical power of the results was 
reduced.121,122 Based on the evidence provided by this and other clinical trials, the 
United States Food and Drug Administration (FDA) issued an Emergency Use 
Authorization (EUA) on August 23 for the use of CCP.124 In its reasoning for granting the 
EUA, the FDA noted the possible benefits of this treatment appeared to outweigh the 
potential risks of its use.125 However, the Infectious Diseases Society of America made 
the recommendation that CCP only be used in the context of a clinical trial.126  
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Randomized controlled trials since that point have yielded mixed results. A trial 
from the Randomised Evaluation of COVID-19 therapy (RECOVERY) series of trials was 
conducted with 11,558 participants.127 This trial found no significant difference in 
survival or other clinical outcomes, and the results were consistent across all 
subgroups.127 The authors of this study also performed a meta-analysis on nine other 
randomized trials and determined that, across all of those trials, CCP does not improve 
mortality.127 Conversely, Libster et al. (2021) conducted a trial with 160 older adult 
patients with CCP administration within 72 hours of mild COVID-19 symptom onset.128 
They found that CCP administration reduced the risk of progression to severe disease by 
48% as compared to the placebo group.128 The treatment group also had a reduced risk 
of all secondary end points.128 A retrospective analysis of 3082 patients from across the 
US found that transfusion of plasma with high antibody levels was associated with a 
lower risk of death in patients not receiving mechanical ventilation.129 This study also 
found a lower risk of death in those who received plasma within 72 hours of diagnosis, 
reinforcing the results from Libster et al.129 Therefore, the FDA modified the EUA for CCP 
on March 9, 2021, limiting the authorization to the use of high titer CCP for the 
treatment of hospitalized patients early in the disease course.130 Low titer CCP use is not 
authorized.130 
 
N. SARS-CoV-2 Structure and Entry 
 SARS-CoV-2, like other coronaviruses, is an enveloped virus with a Spike (S) 
glycoprotein on the surface of the particle.131 The structure of the virion is shown in 
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Figure 21A. The S protein is a Class I fusion protein that exists in a trimeric 
conformation.132,133 Like other Class I fusion proteins, this S protein binds to host cell 
receptors and can undergo a post-translational cleavage event to be able to fuse with 
the cell membrane.133 In the case of SARS-CoV-2, the protein is cleaved by the protease 
furin and TMPRSS2.133,134 Just like SARS-CoV (also known as SARS-CoV-1), the etiologic 
agent of SARS, the SARS-CoV-2 S protein uses the angiotensin-converting enzyme 2 
(ACE2) on the surface of mammalian cells as an entry receptor.106,135 The S1 subunit 
includes the receptor binding domain, which can be concealed (“down”) or exposed 
(“up”), as shown in Figure 21B. During the entry process, the (RBD) will bind to ACE2 
when it is exposed.131-133 This binding event can trigger the other two RBDs in the trimer 
to also bind other ACE2 proteins, opening up the center of the S trimer (Figure 21C).133 
RBD binding to ACE2 causes a conformational change, triggering the fusion peptide of S2 
to fuse with the host cell membrane.133 Therefore, the interaction between ACE2 and 
the RBD of the S1 subunit of the S protein is the critical step in SARS-CoV-2 entry. 
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Figure 21. SARS-CoV-2 Structure and ACE2-Binding. (A) Structure of SARS-CoV-2 virion.136 (B) Ribbon 
structure of S protein with RBD in down (left) and up (right) conformations.132 The RBD is shown in green, 
the fusion peptide is in turquoise, the site of proteolytic cleavage is circled in black, and S2 is red. (C) 
Sequential binding of the S trimer to ACE2 on the surface of a cell.133 The S monomers are shown in blue, 
rosy brown, and gold, and ACE2 is green. “Each step shows two views of the spike complexes: a trimer 




O. Antibody Neutralization of SARS-CoV-2 
 Antibodies, especially those with neutralizing abilities, are essential for immunity 
to any pathogen. The RBD is strongly immunodominant, and it is the target of 90% of 
the neutralizing antibodies to the virus.137 Because of this strong immunodominance, 
many monoclonal antibody (mAb) therapies and drugs that target the RBD or the S 
protein more broadly are in development.138 In another indication of the 
immunogenicity of the spike protein, the SARS-CoV-2 virus has been shown to mutate 
its RBD to evade neutralizing antibodies (nAbs).139,140 On December 9, 2020, it was 
reported that a healthcare worker in Brazil presented with two separate clinical 
episodes of COVID-19.141 Upon sequencing, it was determined that these two infections 
were caused by two different lineages of SARS-CoV-2: B.1.1.33 and B.1.1.28.141 After 
further analysis, Resende et al. discovered that this sample of B.1.1.28 responsible for 
reinfection contained an E484K mutation in the S protein, a position known to be part of 
an epitope for neutralizing antibody binding.141 They also determined that this variant 
was circulating in multiple states across Brazil.141 The ability of the virus to mutate to 
evade memory-generated antibodies that target the spike protein may make CCP and 
vaccination efforts for COVID-19 much more challenging. 
 
P. Summary 
 Because of the newest EUA for CCP, it is necessary to analyze donated serum 
samples to determine the level of neutralizing titers.130 Klein et al. (2020) used virus 
neutralization assays and ELISAs to test the amounts of nAbs.142 Their process of 
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collecting and analyzing donor plasma samples is shown in Figure 22. They showed that 
some subcategories of donors generated more nAbs than others, particularly in men, 
people who are older, and people who have previously been hospitalized for COVID-
19.142 Developing a viable ELISA test for neutralizing titers is important, however, 
because of the challenges associated with the other method used by Klein et al.142 
Specifically, that method requires the use of live, viable virus, which necessitates a BSL-3 
clearance.142 
Figure 22. Process of Collecting and Screening Donor CCP Samples. Adapted from Klein et al. (2020).142 
 
 Here we expressed the RBD and the full-length S protein of SARS-CoV-2. We 
anticipate that our proteins will be able to functionally bind ACE2 and be bound by anti-
SARS-CoV-2 antibodies. Additionally, we optimized a competition ELISA as a surrogate 
method to measure relative levels of nAbs in donor plasma samples. Finally, we 
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analyzed correlation between RBD-ACE2 blocking antibody levels, ELISA titer, and virus 




Materials and Methods 
Plasmid Design and Cloning 
 The plasmids for the receptor binding domain (RBD) and Spike protein from 
SARS-CoV-2 used were both described in Amanat et al.143 In the Spike protein, one Ala 
replaced the polybasic/furin cleavage site (RRAR) (Figure 23A). Additionally, a thrombin 
cleavage site, T4 foldon tetramerization domain, and 6x histidine tag replaced the 
transmembrane and endodomain at the 3’ end of the gene. The RBD also had a histidine 
tag inserted at the 3’ end (Figure 23B). 
Figure 23. Plasmid Design of SARS-CoV-2 Proteins. Design for the Spike (A) and RBD (B) plasmids. The 
signal peptide is shown in yellow, the RBD is red, and the His tag is in green. The plasmids are described in 
Amanat et al.143 
 
Transformation into E. coli and Plasmid Preparation 
 The SARS-CoV-2 RBD and SARS-CoV-2 SPIKE plasmids were generated in the lab 
of Dr. Andrew Pekosz. The plasmids were then transformed into XL-10 Gold® 
Ultracompetent Cells (Agilent Technologies, Cat. #200314). The transformation 
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procedure and plasmid preparation procedures are detailed in the Methods section in 
Part I.  
 
Protein Production, Purification, and Analysis 
HEK293T Cell Transfection 
 The plasmids were transfected into Human Embryonic Kidney 293T (HEK293T) 
cells using either jetPRIME Reagent (Polyplus, Cat. #114-15) or polyethylenimine (PEI) 
using the procedure outlined in HEK293T Cell Transfection in Part I (p. 23). Proteins were 
purified using nickel-NTA beads (or IMAC FPLC column) and analyzed by SDS-PAGE and 
western blotting, as described in the Part I Methods. 
 
Size Exclusion Purification of RBD 
 To remove any proteins that were significantly larger or smaller, the RBD elute 
was further purified by size. For the RBD protein, the elute was first passed through an 
Amicon Ultra-2mL 50kD Centrifugal Filter (Millipore, Cat. #UFC205024) to remove larger 
proteins (the RBD construct was about 35kD). Next, the flow-through that contained the 
protein was passed through a Pierce™ 10kD Concentrator (Thermo, Cat. #88513) to 
remove any low molecular weight proteins. All fractions were run via SDS-PAGE or 
western blot to confirm the location of the desired protein. 
 
Testing Activity of Recombinant RBD 
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 An ELISA assay was performed to test the ability of recombinant RBD to bind to 
ACE2. A half-area 96-well ELISA plate was coated with serial dilutions of mFc tagged RBD 
(GenScript, Cat. #Z03491-100), His-tagged Spike S1 (GenScript, Cat. #Z03485-100), or in-
house expressed recombinant RBD, each starting at concentrations of 4µg/mL, and the 
plate was stored overnight at 4˚C. All dilutions were done in 1x PBS. The next day, the 
plate was incubated with ELISA Blocking Buffer (1x PBS, 0.1% Tween 20, 1% BSA) for 1 
hour. 2µg/mL of ACE-2 Fc Chimera, Human (GenScript, Cat. #Z03484-100) was added to 
each well and was allowed to incubate for 1 hour at room temperature. 1:5000 
ACE2/Angiotensin-Converting Enzyme 2, Rabbit PAb (Sino Biological, Cat. #10108-T56) 
primary antibody, 1:2500 Anti-rabbit IgG (H+L) (Goat) Antibody Peroxidase Conjugated 
(Min x Human Serum Proteins) (Rockland, Cat. #611-1322-0100) secondary antibody, 
and HRP substrate were used to detect binding of ACE2 to RBD. 
 
Plasma Sample Analysis 
Convalescent Plasma Samples 
 Plasma A+ 6-23-2020; CP-COVID 18-6-2020; and CP-COVID A- 6-23-2020 were 
obtained from Dr. Arturo Casadevall’s laboratory to optimize assays.  
 
Ambulatory Plasma Samples 
 Ambulatory plasma samples (n=86) were collected by Dr. Yukari Manabe.144 Dr. 




Optimization of ELISA using Convalescent Plasma 
 Convalescent samples Plasma A+ 6-23-2020; CP-COVID 18-6-2020; and CP-COVID 
A- 6-23-2020 were used to optimize ELISA conditions. Antibody titer was tested against 
both the RBD domain and the S1 subunit. The parameters optimized include the 
concentration and identity of the coating antigen, the length of incubation, the choice of 
secondary antibody, the substrate used, and the assay format (96-well, half-area 96-
well, and 384-well plates). The assay after optimization was conducted as follows: 
Wells of a half-area 96-well plate were coated with 0.5µg/mL of either RBD 
(GenScript, Cat. #Z03491-100) or S1 (GenScript, Cat. #Z03485-100) and stored overnight 
at 4˚C. The next day, ELISA Blocking Buffer (1x PBS, 0.1% Tween 20, 1% BSA) was added 
to each well and incubated for 1-2 hours. 2-fold serial dilutions of these plasma samples 
in ELISA Blocking Buffer were performed in triplicate, starting at a 1:40 dilution. The 
samples were added to the plate and incubated for 1 hour at room temperature. Plates 
were washed 3 times with Wash Buffer (1x PBS, 0.1% Tween 20), and incubated with 
1:10000 diluted Goat Anti-Human IgG (H+L)-HRP (Southern Biotech, Cat. #2016-05). 
Then, BioFX TMB Super Sensitive One Component HRP Microwell Substrate (Surmodics, 
Cat. #TMBS-0100-01) was added to each well. After 2 minutes, an equal volume of TMB 
Stop Reagent, 450nm (Bioworld, Cat. #21530071-1) was added to each well. The plate 
was read at 450nm-650nm. 
 
ELISA Using Ambulatory Plasma 
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 Plasma samples were centrifuged for 15 minutes at 12,000rpm and 4˚C to 
remove debris. Each plasma sample was 3-fold serially diluted in duplicate, starting at 
1:50. Normal hAB Plasma (Sigma) was used as a negative control. These dilutions were 
made on the same day the plate was coated, and the dilution plate was stored overnight 
at 4˚C. The ELISA was performed as described above, and bound anti-RBD antibodies 
were detected using anti-human IgG (H+L) (1:10000 dilution) and BioFX TMB HRP 
Substrate. A total of 57 plasma samples were tested by this assay. 
 
Optimization of Competition ELISA to Measure RBD-ACE2 Blocking Activity using 
Convalescent Plasma  
 The three convalescent plasma samples (Plasma A+ 6-23-2020; CP-COVID 18-6-
2020; and CP-COVID A- 6-23-2020) were tested in a competition ELISA to evaluate the 
levels of antibodies blocking binding of RBD to ACE2. 2-fold serial dilutions of the plasma 
samples in triplicate, starting at a 1:5 dilution, were used in these optimization assays. 
The parameters optimized include the concentration and identity of coating antigen, the 
duration of competition (i.e., incubation time of plasma with RBD), the choice of 
secondary antibody and substrate, and the assay format (96-well, half-area 96-well, and 
384-well plates). The assay after optimization was conducted as follows: 
 Half-area 96-well ELISA plates were coated with 1µg/mL of mFc-tagged RBD and 
stored overnight at 4˚C. The following day, ACE-2 Fc Chimera, Human (GenScript, Cat. 
#Z03484-100) (2µg/mL final concentration per well) was added 2-fold serially diluted 
individual plasma samples in duplicate (starting at 1:2.5 dilution) and incubated for 5 
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minutes. This mixture was added to the RBD-coated plate and incubated for 1 hour at 
room temperature. Following 3 washes, ACE2/Antiotensin Converting Enzyme 2, Rabbit 
PAb (Sino Biological, Cat. #10108-T56) primary antibody and Anti-rabbit IgG (H+L) (Goat) 
Antibody Peroxidase Conjugated (Min x Human Serum Proteins) (Rockland, Cat. #611-
1322-0100) secondary antibody were used and absorbance was measured at 450nm. 
Wells with no plasma were used as controls, and the absorbance OD from these wells 
were set as 100% ACE2 binding (max, no competition). The blocking activity (%) was 




where ODMax is the optical density of the wells that only included ACE2 (no plasma 
added). A total of 86 plasma samples were tested by this method. 
 
Statistical Analysis 
 As described in Klein et al. (2020), the area under the curve (AUC) values were 
calculated by graphing the normalized OD values against the ELISA sample dilutions.142 
Correlations were calculated using Pearson’s correlation coefficient. 
 
Study Approval 
 Per Klein et al. (2020), “The Johns Hopkins University School of Medicine IRB 
reviewed and approved the sample collection protocols and overall study. All 





Expression of RBD and Spike in HEK293T Cells 
 The SARS-CoV-2 receptor binding domain (RBD) and full-length Spike protein 
plasmids were transfected into HEK293T cells to test for protein expression. Proteins in 
the culture supernatants were pulled down His-Tag Isolation and Pulldown using 
Dynabeads™. After washing, the beads were boiled, and samples were analyzed by SDS-
PAGE under reducing conditions. The arrows in Figure 24A point to the bands 
corresponding to recombinant Spike (134kD) and RBD (35kD) proteins, respectively. 
Western blot using anti-His antibodies confirmed expression of the proteins (Figure 




Figure 24. HEK293T Cell Expression of RBD and Spike Proteins. (A) Gel indicating expression of RBD and 
Spike in HEK293T cells. (B) Western blot showing Spike and RBD expression. The Spike protein (yellow 
arrow) is about 134kD, and the RBD protein (black arrow) is around 35kD. 
 
Recombinant RBD Purification 
 Recombinant RBD protein was purified using a HisPur™ Ni-NTA Spin Column to 
isolate the RBD protein. Once the supernatant was passed through the column, the 
column was washed 7 times each with 25mM imidazole and 40mM imidazole in 20mM 
Sodium Phosphate Buffer pH 7.4, 300mM NaCl (25mM and 40mM IBB). Next, the 
protein was eluted stepwise with 100mM imidazole, 300mM imidazole, and 500mM 
imidazole. A typical purification is shown in Figure 25A. Higher molecular weight 
contaminating proteins were effectively removed by passing the elute through a 50kD 
filter, and the flow-through containing RBD was concentrated using a 10kD filter. The 
SDS-PAGE gel in Figure 25B shows the 50kD top concentrate, which contains the larger 
impurities, and the 10kD top concentrate showing the purified RBD sample. While some 
protein was lost in the 50kD filtration, the size exclusion was effective in providing 
highly pure RBD protein. An ELISA assay with a 4µg/mL RBD coating was performed to 
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test the ability of the recombinant RBD protein to bind ACE2. The RBD protein 
demonstrates a dose-dependent binding affinity for ACE2 (Figure 25C). 
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Figure 25. Purification of RBD Construct. (A) Typical purification of RBD in increasing concentrations of 
imidazole. The protein is primarily visible in the 100mM, 300mM, and 1st 500mM elutes. The RBD protein 
is about 35kD. (B) Size exclusion purification of RBD comparing the top concentrate from a 50kD filter to 
the protein purified through sequential passaging between 50kD and 10kD filters. (C) Results of ELISA 
testing the affinity of RBD for ACE2, its molecular target. 
 
Spike Purification 
 Like with the RBD, we commenced with purifying the Spike protein once we 
established that it was being produced. Its purification procedure on the HisPur™ Ni-
NTA Spin Column was identical to that done for RBD (Figure 26A). 
 Due to low expression levels of the full-length Spike protein, larger volumes of 
culture supernatants were purified. The protein was also purified on a 1mL Bio-Scale 





Figure 26. Purification of Spike Protein. (A) Typical purification of Spike in increasing concentrations of 
imidazole. The protein is primarily visible in the 300mM and 1st 500mM imidazole fractions. (B) A280 
chromatogram of IMAC purification of Spike protein. The black lines represent the concentration of 
imidazole used in the gradient. 
 
Evaluating Binding of Commercial RBD and S1 to ACE2 
 An ELISA assay was performed to test the ability of commercially available RBD 
(GenScript, Cat. #Z03491-100) and S1 (GenScript, Cat. #Z03485-100) proteins to bind 
86 
 
ACE2. The plate was coated with 4µg/mL of RBD or S1. Our results suggest that both of 
the purchased proteins functionally bind ACE2 in a dose-dependent manner (Figure 27). 
As a result, both proteins were used in our experiments with convalescent plasma 
samples, and this RBD was used for our tests with ambulatory plasma samples. 
Figure 27. RBD and S1 Binding to ACE2. The commercial RBD is shown in pink, while the commercial S1 is 
in gray. 
 
Analysis of Convalescent Plasma Samples by ELISA and Competition ELISA 
 First, the convalescent plasma samples (Plasma A+ 6-23-2020, CP-COVID 18-6-
2020, and CP-COVID A- 6-23-2020) were evaluated for the level of anti-Spike antibodies 
by ELISA. Our results show that sample CP-COVID 18-6-2020 sample had the highest 
level of antibodies when tested against both RBD and the full-length S1 subunit a strong 
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affinity for either the RBD or the S1 (Figure 28A). This sample also demonstrated high 
levels of blocking activity in the competition assay (Figure 28B). 
Figure 28. Analysis of Convalescent Plasma. (A) ELISA and (B) Competition ELISA. S-RBD refers to the RBD 
domain, and S1-FL refers to the full-length S1 subunit. 
 
Analysis of Ambulatory Plasma Samples to Assess Levels of RBD-ACE2 Blocking 
Antibodies 
 Competition assays were performed using serially-diluted (starting at 1:5) 
ambulatory plasma samples (n=86). Dilutions of plasma samples were mixed with 
2µg/mL ACE2, and this mixture was added to an ELISA plate coated with 1µg/mL RBD. 
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The amount of ACE2 that bound to RBD is proportional to the level of anti-RBD 
antibodies that can interfere with its binding to ACE2. Our experimental design of 
adding the receptor, ACE2, and the antibodies simultaneous allowed us to evaluate the 
competition for binding RBD in a more stringent manner. Blocking activity was 
calculated by comparing the amount of ACE2 binding to RBD at different dilutions of the 
individual samples compared to binding in the absence of antibody. Figure 29A shows a 
non-linear fit of the data. It is evident from our data that the level of RBD-ACE2 blocking 
antibody differed between samples. 
 Virus neutralization titer (NT) is currently considered the gold standard assay, as 
it strongly associates with protection from infection. Therefore, we assessed the 
association between NT and our ELISA. Since a majority of the samples did not show 
>50% inhibition in the competition assay, even at the lowest plasma dilution, we opted 
to use the activity observed at 1:5 dilution. Importantly, this was the dilution that 
demonstrated robust activity for most of the samples and also correlated well when 
tested pairwise against other, higher dilutions (Figure 29B). Interestingly, the level of 
RBD-ACE2 blocking activity strongly associated with virus neutralization titers 
(conducted by Dr. Pekosz) (Figure 29C).142 A similar association was also observed 
between NT and anti-RBD titer (Figure 29D). As expected, our data also demonstrated a 
strong correlation between total anti-RBD titer and the level of RBD-ACE2 blocking 
activity in the corresponding plasma samples (Figure 29E). The high degree of 
correlation observed between RBD-ACE2 blocking activity and virus neutralization 
therefore offers a relatively simple biochemical assay to monitor/measure functional 
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antibodies. This assay may also be helpful in challenging environments as a surrogate to 
the gold standard NT assay. 
Figure 29. Analysis of Ambulatory Plasma for RBD-ACE2 Blocking Antibodies. (A) RBD-ACE2 blocking 
activity (%) measured in individual plasma. Data was fitted using a 4-parameter nonlinear sigmoidal curve. 
(B) Correlation between blocking activity measured at 1:5 vs. 1:10 plasma dilutions. (C) Correlation 
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between neutralizing antibody titer (NT) measured as area under the curve (AUC) vs. RBD-ACE2 blocking 
activity at 1:5 dilution. (D) Correlation between neutralizing antibody titer (NT-AUC) vs. anti-RBD titer 
AUC. (E) Correlation between RBD-ACE2 blocking activity at 1:5 dilution vs. anti-RBD titer AUC. Pearson’s 
correlation coefficient (r) and p-value are indicated for each comparison. Data on neutralizing titers 




 The ongoing COVID-19 pandemic is the most impactful major public health event 
since the 1918 influenza pandemic. In addition to the millions who have succumbed to 
the disease so far, more will die as the pandemic continues.117 It may also take years or 
decades to fully appreciate the latent health effects associated with the pandemic. For 
example, a 2009 study from Mazumber et al. found that prenatal exposure to the 1918 
H1N1 influenza virus resulted in a significant increase in risk of heart disease above the 
age of 60.145 Additionally, men between the ages of 19 and 27 who born in 1919 were 
significantly shorter than those born in surrounding years.145 COVID-19 has also been 
found to be associated with an increased risk of stroke, possibly related to the presence 
of megakaryocytes in capillaries in the brain.146,147 Additionally, the pandemic has also 
caused widespread socioeconomic changes that may take time to revert back to their 
pre-pandemic states.148 
 Definitive progress has been made in the process of COVID-19 vaccinations. On 
December 11, 2020, the FDA issued an EUA for a vaccine developed by Pfizer-BioNTech. 
This vaccine demonstrated an efficacy of 95% in preventing COVID-19 at least 7 days 
after receiving the booster.149 On December 18, 2020, just a week after the EUA for the 
first COVID-19 vaccine, the FDA issued an EUA for a vaccine developed by Moderna.150 
This vaccine also demonstrated a high efficacy of 94.1% 7 days after the second dose. 
Both EUAs were reissued on February 25.149,150 The FDA issued a third EUA on February 
27 for one manufactured by Janssen.151 The Janssen vaccine, which is a single dose, was 
66.9% effective 14 days after vaccination and 66.1% effective after 28 days.151 
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Additionally, several other vaccines are still in development or have been dosed to 
patients in other countries.152,153 
 Here, we describe the expression of two recombinant proteins that comprise 
components of the SARS-CoV-2 Spike protein, the receptor binding domain (RBD) of the 
S1 subunit and the full-length protein. We demonstrated that we could express the RBD 
in HEK293T cells. We were successful in purifying the proteins, confirmed by SDS-PAGE 
and western blot. Using an ELISA, we demonstrated that our RBD was able to bind ACE2, 
its host cell receptor, albeit less so than RBD or full-length S1 bought commercially. We 
have demonstrated the design, expression, purification, and biological activity of the 
SARS-CoV-2 RBD. 
 We have also shown expression of the Spike protein, confirmed by SDS-PAGE 
and western blot. We purified Spike using nickel beads or by chromatography on an 
IMAC column. However, it was challenging to concentrate the protein; attempts to do 
so using a 100kD cut-off spin column were unsuccessful (data not shown). Because of 
the challenges in purification, we did not proceed with testing test the protein’s ability 
to bind ACE2.  
 We have also developed multiple assays for testing COVID-19 convalescent 
plasma (CCP) samples. ELISAs testing plasma binding to RBD or the full-length S1 subunit 
showed agreement in binding titers to both proteins. The assay allowed us to 
differentiate between high-binding and low-binding plasma samples. We standardized 
an ELISA that measures the ability of plasma samples to bind RBD. This assay shows a 
high correlation (r=0.6900, p<0.0001) to neutralizing antibody (nAb) titers measured 
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using a neutralization assay in the lab of Dr. Andrew Pekosz, suggesting the reliability of 
our standardized assay. 
 Additionally, we have created an ELISA assay that tests the ability of a plasma 
sample to block the association between RBD and human ACE2. Our assay is able to 
distinguish between high-, medium-, and low-titer CCP samples. All blocking activity 
exhibits a similar dose-dependent effect, and the blocking activity is relatively consistent 
regardless of dilution. Our two ELISAs, the one which measures RBD binding and the 
competition ELISA, correlate with each other (r=0.7442, p<0.0001). Critically, the 
competition ELISA also correlates with the nAb titers calculated by neutralization assays 
(r=0.7785, p<0.0001).  
 The high correlations with data from neutralization assays show that the 
combination of our two ELISAs, the one measuring binding ACE2 and the one showing 
inhibition of RBD-ACE2 association, results in a viable alternative for measuring and 
assessing nAb titers. Given the updated EUA limiting the use of CCP to those with high 
nAb titers, it is critical to identify those with high blocking ability.130 However, 
neutralization assays are dangerous and cumbersome, requiring live, viable virus and a 
BSL-3 clearance. Our assays allow labs to generate and evaluate neutralization data 
without the need for actual virus samples or a BSL-3 facility. Additionally, our ELISAs can 
quickly evaluate numerous plasma samples at a time.  
 Overall, we have successfully expressed, purified, and demonstrated biological 
activity of the RBD and full-length Spike protein from SARS-CoV-2. We have 
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demonstrated that our designed ELISAs can determine the level of nAb titer in a given 
plasma sample, saving time and avoiding the handling of live virus. 
 
Future Directions 
 In our competition assay, most samples did not reach greater than 50% 
inhibition, and no samples reached 100% inhibition. However, it is possible that the 
samples would show a greater degree of blocking if we exposed the RBD to the plasma 
first, followed by incubation with ACE2 in a second step. It would be worthwhile to test 
this alternative competition. However, considering that our current assay correlates 
strongly with the data from the neutralization assay, we would expect that this 
modification would not drastically alter the value of the correlation coefficient. 
It would be beneficial to optimize the expression and purification of SARS-CoV-2 
Spike proteins and Spike components like the RBD. Additionally, once the Spike proteins 
of SARS-CoV-2 variants have been sequenced, we can quickly and effectively generate 
those Spike variants. We could then use the mutant RBD domains as coatings for our 
ELISAs to test how effectively CCP samples protect against the viral variants. We could 
also use these ELISAs to examine how effectively the various COVID-19 vaccines can 
generate antibodies that neutralize various viral strains. Additionally, CCP could still be 
an important prophylactic measure for those patients who are contraindicated for the 





1. Cunha CB, Cunha BA. Brief history of the clinical diagnosis of malaria: From 
hippocrates to osler. J Vector Borne Dis. 2008;45(3):194-199. 
2. WHO. Global technical strategy for malaria 2016-2030. ; 2015:32. 
https://www.who.int/malaria/publications/atoz/9789241564991/en/. 
3. WHO. Eliminating malaria. ; 2016. 
https://www.who.int/malaria/publications/atoz/eliminating-malaria/en/. 
4. WHO. World malaria report 2020. ; 2020. 
https://www.who.int/publications/i/item/9789240015791. 
5. Johns Hopkins University and Medicine. Johns hopkins coronavirus resource center. 
https://coronavirus.jhu.edu/. Updated 2021. Accessed January 26, 2021. 
6. Phillips MA, Burrows JN, Manyando C, van Huijsduijnen RH, Van Voorhis WC, Wells 
TNC. Malaria. Nat Rev Dis Primers. 2017;3:17050. doi: 10.1038/nrdp.2017.50 [doi]. 
7. Cowman AF, Healer J, Marapana D, Marsh K. Malaria: Biology and disease. Cell. 
2016;167(3):610-624. doi: S0092-8674(16)31008-X [pii]. 





9. Gubbels MJ, Duraisingh MT. Evolution of apicomplexan secretory organelles. Int J 
Parasitol. 2012;42(12):1071-1081. doi: S0020-7519(12)00232-9 [pii]. 
10. Yotoko K, Elisei C. Malaria parasites (apicomplexa, haematozoea) and their 
relationships with their hosts: Is there an evolutionary cost for the specialization? J Zool 
Syst Evol Res. 2006;44(4):265-273. 
11. Milner DA,Jr. Malaria pathogenesis. Cold Spring Harb Perspect Med. 
2018;8(1):a025569. doi: 10.1101/cshperspect.a025569. doi: 
10.1101/cshperspect.a025569 [doi]. 
12. Su XZ, Lane KD, Xia L, Sá JM, Wellems TE. Plasmodium genomics and genetics: New 
insights into malaria pathogenesis, drug resistance, epidemiology, and evolution. Clin 
Microbiol Rev. 2019;32(4):e00019-19. Print 2019 Sep 18. doi: 10.1128/CMR.00019-19 
[doi]. 
13. Gachelin G, Garner P, Ferroni E, Tröhler U, Chalmers I. Evaluating cinchona bark and 
quinine for treating and preventing malaria. J R Soc Med. 2017;110(1):31-40. doi: 
10.1177/0141076816681421 [doi]. 
14. Barnett R. Malaria. Lancet. 2016;387(10037):2495-1. doi: S0140-6736(16)30799-1 
[pii]. 
15. Slater AF. Chloroquine: Mechanism of drug action and resistance in Plasmodium 
falciparum. Pharmacol Ther. 1993;57(2-3):203-235. doi: 0163-7258(93)90056-J [pii]. 
97 
 
16. Mita T, Kaneko A, Lum JK, et al. Recovery of chloroquine sensitivity and low 
prevalence of the Plasmodium falciparum chloroquine resistance transporter gene 
mutation K76T following the discontinuance of chloroquine use in malawi. Am J Trop 
Med Hyg. 2003;68(4):413-415. 
17. Blasco B, Leroy D, Fidock DA. Antimalarial drug resistance: Linking Plasmodium 
falciparum parasite biology to the clinic. Nat Med. 2017;23(8):917-928. doi: 
10.1038/nm.4381 [doi]. 
18. Kim J, Tan YZ, Wicht KJ, et al. Structure and drug resistance of the Plasmodium 
falciparum transporter PfCRT. Nature. 2019;576(7786):315-320. doi: 10.1038/s41586-
019-1795-x [doi]. 
19. Laufer MK, Thesing PC, Eddington ND, et al. Return of chloroquine antimalarial 
efficacy in malawi. N Engl J Med. 2006;355(19):1959-1966. doi: 355/19/1959 [pii]. 




21. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum 
malaria. N Engl J Med. 2009;361(5):455-467. doi: 10.1056/NEJMoa0808859 [doi]. 
98 
 
22. WHO. Status report on artemisinin and ACT resistance. ; 2015. 
https://www.who.int/malaria/publications/atoz/update-artemisinin-resistance-
sep2015/en/. 
23. Ménard D, Khim N, Beghain J, et al. A worldwide map of Plasmodium falciparum 
K13-propeller polymorphisms. N Engl J Med. 2016;374(25):2453-2464. doi: 
10.1056/NEJMoa1513137 [doi]. 
24. WHO. Malaria vaccine technology roadmap. 
https://www.who.int/immunization/sage/meetings/2013/april/7_Malaria_Vaccine_TR
M_Final.pdf?ua=1. Updated 2006. Accessed January 31, 2021. 
25. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the 
circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum Vaccin. 2010;6(1):90-
96. doi: 9677 [pii]. 
26. Kaslow DC, Biernaux S. RTS,S: Toward a first landmark on the malaria vaccine 
technology roadmap. Vaccine. 2015;33(52):7425-7432. 
http://www.sciencedirect.com/science/article/pii/S0264410X15013377. doi: 
https://doi.org/10.1016/j.vaccine.2015.09.061. 
27. RTS, S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine 
with or without a booster dose in infants and children in africa: Final results of a phase 




28. White MT, Verity R, Griffin JT, et al. Immunogenicity of the RTS,S/AS01 malaria 
vaccine and implications for duration of vaccine efficacy: Secondary analysis of data 
from a phase 3 randomised controlled trial. Lancet Infect Dis. 2015;15(12):1450-1458. 
doi: S1473-3099(15)00239-X [pii]. 
29. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral 
and vaccine antigens. N Engl J Med. 2007;357(19):1903-1915. doi: 357/19/1903 [pii]. 
30. European Medicines Agency. Summary of opinion: Mosquirix--Plasmodium 
falciparum and hepatitis B vaccine (recombinant, adjuvanted). . 2015. 
31. WHO. Malaria vaccine: WHO position paper--january 2016. Weekly epidemiological 
record. 2016;91(4):33-52. https://www.who.int/wer/2016/WER9104.pdf?ua=1. 
32. Birkett AJ. Status of vaccine research and development of vaccines for malaria. 
Vaccine. 2016;34(26):2915-2920. doi: S0264-410X(16)00294-2 [pii]. 
33. Bannister LH, Hopkins JM, Fowler RE, Krishna S, Mitchell GH. A brief illustrated guide 
to the ultrastructure of Plasmodium falciparum asexual blood stages. Parasitol Today. 
2000;16(10):427-433. doi: S0169-4758(00)01755-5 [pii]. 
34. Besteiro S, Dubremetz JF, Lebrun M. The moving junction of Apicomplexan parasites: 




35. Cowman AF, Tonkin CJ, Tham W, Duraisingh MT. The molecular basis of erythrocyte 
invasion by malaria parasites. Cell Host & Microbe. 2017;22(2):232-245. 
http://www.sciencedirect.com.proxy1.library.jhu.edu/science/article/pii/S19313128173
0286X. doi: https://doi-org.proxy1.library.jhu.edu/10.1016/j.chom.2017.07.003. 
36. Miller LH, Ackerman HC, Su XZ, Wellems TE. Malaria biology and disease 
pathogenesis: Insights for new treatments. Nat Med. 2013;19(2):156-167. doi: 
10.1038/nm.3073 [doi]. 
37. Srinivasan P, Beatty WL, Diouf A, et al. Binding of Plasmodium merozoite proteins 
RON2 and AMA1 triggers commitment to invasion. Proc Natl Acad Sci USA. 
2011;108(32):13275-13280. doi: 10.1073/pnas.1110303108 [doi]. 
38. Kato K. How does toxoplama gondii invade host cells? J Vet Med Sci. 
2018;80(11):1702-1706. doi: 10.1292/jvms.18-0344 [doi]. 
39. Lamarque M, Besteiro S, Papoin J, et al. The RON2-AMA1 interaction is a critical step 
in moving junction-dependent invasion by apicomplexan parasites. PLoS Pathog. 
2011;7(2):e1001276. doi: 10.1371/journal.ppat.1001276 [doi]. 
40. Silvie O, Franetich JF, Charrin S, et al. A role for apical membrane antigen 1 during 
invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem. 
2004;279(10):9490-9496. doi: M311331200 [pii]. 
101 
 
41. Tufet-Bayona M, Janse CJ, Khan SM, Waters AP, Sinden RE, Franke-Fayard B. 
Localisation and timing of expression of putative Plasmodium berghei rhoptry proteins 
in merozoites and sporozoites. Mol Biochem Parasitol. 2009;166(1):22-31. doi: 
10.1016/j.molbiopara.2009.02.009 [doi]. 
42. Yang ASP, Lopaticki S, O'Neill MT, et al. AMA1 and MAEBL are important for 
Plasmodium falciparum sporozoite infection of the liver. Cell Microbiol. 
2017;19(9):10.1111/cmi.12745. Epub 2017 May 18. doi: 10.1111/cmi.12745 [doi]. 
43. Ishino T, Murata E, Tokunaga N, et al. Rhoptry neck protein 2 expressed in 
Plasmodium sporozoites plays a crucial role during invasion of mosquito salivary glands. 
Cell Microbiol. 2019;21(1):e12964. doi: 10.1111/cmi.12964 [doi]. 
44. Srinivasan P, Yasgar A, Luci DK, et al. Disrupting malaria parasite AMA1-RON2 
interaction with a small molecule prevents erythrocyte invasion. Nat Commun. 
2013;4:2261. doi: 10.1038/ncomms3261 [doi]. 
45. Harris KS, Casey JL, Coley AM, et al. Binding hot spot for invasion inhibitory 
molecules on Plasmodium falciparum apical membrane antigen 1. Infect Immun. 
2005;73(10):6981-6989. http://iai.asm.org/content/73/10/6981.abstract. doi: 
10.1128/IAI.73.10.6981-6989.2005. 
46. Harris KS, Casey JL, Coley AM, et al. Rapid optimization of a peptide inhibitor of 
malaria parasite invasion by comprehensive N-methyl scanning. J Biol Chem. 
2009;284(14):9361-9371. doi: 10.1074/jbc.M808762200 [doi]. 
102 
 
47. Tyler JS, Boothroyd JC. The C-terminus of Toxoplasma RON2 provides the crucial link 
between AMA1 and the host-associated invasion complex. PLoS Pathog. 
2011;7(2):e1001282. doi: 10.1371/journal.ppat.1001282 [doi]. 
48. Vulliez-Le Normand B, Tonkin ML, Lamarque MH, et al. Structural and functional 
insights into the malaria parasite moving junction complex. PLoS Pathog. 
2012;8(6):e1002755. doi: 10.1371/journal.ppat.1002755 [doi]. 
49. Srinivasan P, Ekanem E, Diouf A, et al. Immunization with a functional protein 
complex required for erythrocyte invasion protects against lethal malaria. Proc Natl 
Acad Sci USA. 2014;111(28):10311-10316. doi: 10.1073/pnas.1409928111 [doi]. 
50. Srinivasan P, Baldeviano GC, Miura K, et al. A malaria vaccine protects aotus 
monkeys against virulent Plasmodium falciparum infection. NPJ Vaccines. 
2017;2:10.1038/s41541-7. Epub 2017 May 22. doi: 14 [pii]. 
51. Xiao S. Engineering a self-targeting entry inhibitor for malaria prophylaxis. Johns 
Hopkins University Bloomberg School of Public Health; 2019. 
52. Druilhe P, Pérignon JL. Mechanisms of defense against P. falciparum asexual blood 
stages in humans. Immunol Lett. 1994;41(2-3):115-120. doi: 0165-2478(94)90118-X [pii]. 
53. Boyle MJ, Reiling L, Feng G, et al. Human antibodies fix complement to inhibit 
Plasmodium falciparum invasion of erythrocytes and are associated with protection 
against malaria. Immunity. 2015;42(3):580-590. doi: S1074-7613(15)00087-4 [pii]. 
103 
 
54. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the 
monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual 
blood stages. J Exp Med. 1995;182(2):409-418. doi: 95355840 [pii]. 
55. Jafarshad A, Dziegiel MH, Lundquist R, Nielsen LK, Singh S, Druilhe PL. A novel 
antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria 
requires costimulation of monocytes FcgammaRII and FcgammaRIII. J Immunol. 
2007;178(5):3099-3106. doi: 178/5/3099 [pii]. 
56. Jafari R, Zolbanin NM, Rafatpanah H, Majidi J, Kazemi T. Fc-fusion proteins in 
therapy: An updated view. Curr Med Chem. 2017;24(12):1228-1237. doi: 
10.2174/0929867324666170113112759 [doi]. 
57. Strohl WR. Fusion proteins for half-life extension of biologics as a strategy to make 
biobetters. BioDrugs. 2015;29(4):215-239. doi: 10.1007/s40259-015-0133-6 [doi]. 
58. Capon DJ, Chamow SM, Mordenti J, et al. Designing CD4 immunoadhesins for AIDS 
therapy. Nature. 1989;337(6207):525-531. doi: 10.1038/337525a0 [doi]. 
59. Sleep D. Albumin and its application in drug delivery. Expert Opin Drug Deliv. 
2015;12(5):793-812. doi: 10.1517/17425247.2015.993313 [doi]. 
60. Zorzi A, Linciano S, Angelini A. Non-covalent albumin-binding ligands for extending 
the circulating half-life of small biotherapeutics. Medchemcomm. 2019;10(7):1068-1081. 
doi: 10.1039/c9md00018f [doi]. 
104 
 
61. Yeh P, Landais D, Lemaître M, et al. Design of yeast-secreted albumin derivatives for 
human therapy: Biological and antiviral properties of a serum albumin-CD4 genetic 
conjugate. Proc Natl Acad Sci USA. 1992;89(5):1904-1908. doi: 10.1073/pnas.89.5.1904 
[doi]. 
62. Smith BJ, Popplewell A, Athwal D, et al. Prolonged in vivo residence times of 
antibody fragments associated with albumin. Bioconjug Chem. 2001;12(5):750-756. doi: 
bc010003g [pii]. 
63. Subramanian GM, Fiscella M, Lamousé-Smith A, Zeuzem S, McHutchison JG. 
Albinterferon alpha-2b: A genetic fusion protein for the treatment of chronic hepatitis C. 
Nat Biotechnol. 2007;25(12):1411-1419. doi: nbt1364 [pii]. 
64. Miyakawa N, Nishikawa M, Takahashi Y, et al. Prolonged circulation half-life of 
interferon γ activity by gene delivery of interferon γ-serum albumin fusion protein in 
mice. J Pharm Sci. 2011;100(6):2350-2357. doi: 10.1002/jps.22473 [doi]. 
65. Dennis MS, Zhang M, Meng YG, et al. Albumin binding as a general strategy for 
improving the pharmacokinetics of proteins. J Biol Chem. 2002;277(38):35035-35043. 
doi: M205854200 [pii]. 
66. Miyakawa N, Nishikawa M, Takahashi Y, et al. Gene delivery of albumin binding 
peptide-interferon-gamma fusion protein with improved pharmacokinetic properties 




67. Nilvebrant J, Hober S. The albumin-binding domain as a scaffold for protein 
engineering. Comput Struct Biotechnol J. 2013;6:e201303009. doi: 
10.5936/csbj.201303009 [doi]. 
68. Jonsson A, Dogan J, Herne N, Abrahmsén L, Nygren PA. Engineering of a femtomolar 
affinity binding protein to human serum albumin. Protein Eng Des Sel. 2008;21(8):515-
527. doi: 10.1093/protein/gzn028 [doi]. 
69. Levy OE, Jodka CM, Ren SS, et al. Novel exenatide analogs with peptidic albumin 
binding domains: Potent anti-diabetic agents with extended duration of action. PLoS 
One. 2014;9(2):e87704. doi: 10.1371/journal.pone.0087704 [doi]. 
70. Bridges A, Bistas KG, Jacobs TF. Exenatide. In: StatPearls. Treasure Island (FL): 
StatPearls Publishing LLC; 2020. NBK518981 [bookaccession]. 
71. Orlova A, Jonsson A, Rosik D, et al. Site-specific radiometal labeling and improved 
biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-
binding domain fusion protein. J Nucl Med. 2013;54(6):961-968. doi: 
10.2967/jnumed.112.110700 [doi]. 
72. Altai M, Leitao CD, Rinne SS, et al. Influence of molecular design on the targeting 
properties of ABD-fused mono- and bi-valent anti-HER3 affibody therapeutic constructs. 
Cells. 2018;7(10):164. doi: 10.3390/cells7100164. doi: 10.3390/cells7100164 [doi]. 
106 
 
73. Zhang Y, Guo Z, Cao Z, et al. Endogenous albumin-mediated delivery of redox-
responsive paclitaxel-loaded micelles for targeted cancer therapy. Biomaterials. 
2018;183:243-257. doi: S0142-9612(18)30417-4 [pii]. 
74. Tan H, Su W, Zhang W, Zhang J, Sattler M, Zou P. Albumin-binding domain extends 
half-life of glucagon-like peptide-1. Eur J Pharmacol. 2021;890:173650. doi: S0014-
2999(20)30742-1 [pii]. 
75. Kober L, Zehe C, Bode J. Optimized signal peptides for the development of high 
expressing CHO cell lines. Biotechnol Bioeng. 2013;110(4):1164-1173. doi: 
10.1002/bit.24776 [doi]. 
76. George RA, Heringa J. An analysis of protein domain linkers: Their classification and 
role in protein folding. Protein Eng Des Sel. 2002;15(11):871-879. doi: 
10.1093/protein/15.11.871. 
77. Argos P. An investigation of oligopeptides linking domains in protein tertiary 
structures and possible candidates for general gene fusion. J Mol Biol. 1990;211(4):943-
958. doi: 0022-2836(90)90085-Z [pii]. 
78. Huston JS, Levinson D, Mudgett-Hunter M, et al. Protein engineering of antibody 
binding sites: Recovery of specific activity in an anti-digoxin single-chain fv analogue 




79. Invitrogen. pcDNA 3.1 (+) mammalian expression vector. 
https://www.thermofisher.com/order/catalog/product/V79020#/V79020. Updated 
2021. Accessed February 20, 2021. 
80. Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA,3rd, Smith HO. Enzymatic 
assembly of DNA molecules up to several hundred kilobases. Nat Methods. 
2009;6(5):343-345. doi: 10.1038/nmeth.1318 [doi]. 
81. New England BioLabs. Gibson assembly. https://www.neb.com/applications/cloning-
and-synthetic-biology/dna-assembly-and-cloning/gibson-assembly. Updated 2021. 
Accessed February 22, 2021. 
82. New England BioLabs. NEBuilder HiFi DNA assembly reaction protocol. 
https://www.neb.com/protocols/2014/11/26/nebuilder-hifi-dna-assembly-reaction-
protocol. Updated 2021. Accessed February 22, 2021. 
83. New England BioLabs. NEBio calculator: Ligation calculator. 
https://nebiocalculator.neb.com/#!/ligation. Updated 2021. 





85. Zymo Research. ZymoPURE II plasmid midiprep kit. 
https://files.zymoresearch.com/protocols/_d4200_d4201_zymopure_ii_plasmid_midipr
ep.pdf. 
86. Polyplus. jetPRIME transfection reagent short protocol-DNA transfection. 
https://www.polyplus-transfection.com/wp-content/uploads/2015/08/Short-Protocol-
jetPRIME-DNA-vG.pdf. Accessed February 24, 2021. 
87. Cold Spring Harbor Protocols. Polyethylenimine (PEI), linear (1mg/mL). 
http://cshprotocols.cshlp.org/content/2008/3/pdb.rec11323.full. Accessed March 4, 
2020. 
88. Gibco. Expi293 expression system: Structural biology and inducible expression 
modules user guide. https://assets.thermofisher.com/TFS-
Assets/LSG/manuals/MAN0007814_Expi293_ExpressionSystem_UG.pdf. Updated 2020. 




90. Hober S, Nord K, Linhult M. Protein A chromatography for antibody purification. 





91. Block H, Maertens B, Spriestersbach A, et al. Chapter 27 immobilized-metal affinity 
chromatography (IMAC): A review. Meth Enzymol. 2009;463:439-473. 
https://www.sciencedirect.com/science/article/pii/S0076687909630275. doi: 
https://doi.org/10.1016/S0076-6879(09)63027-5. 
92. Bio-Rad. CHT ceramic hydroxyapatite type II media. https://www.bio-rad.com/en-
us/product/cht-ceramic-hydroxyapatite-type-ii-media?ID=5ded4ec5-ff5a-47b7-bf10-
07253005c83f. Updated 2021. Accessed February 28, 2021. 
93. Bio-Rad. Ceramic hydroxyapatite application guide for process development and 
scale-up. .  




aXMtVHJpcyBHZWwgU3lzdGVt. Updated 2012. Accessed December 18, 2020. 
95. Bhardwaj G, Mulligan VK, Bahl CD, et al. Accurate de novo design of hyperstable 
constrained peptides. Nature. 2016;538(7625):329-335. doi: 10.1038/nature19791 [doi]. 
96. Rocklin GJ, Chidyausiku TM, Goreshnik I, et al. Global analysis of protein folding 
using massively parallel design, synthesis, and testing. Science. 2017;357(6347):168-175. 
doi: 10.1126/science.aan0693 [doi]. 
110 
 
97. Nguyen A, Reyes AE,2nd, Zhang M, et al. The pharmacokinetics of an albumin-
binding fab (AB.fab) can be modulated as a function of affinity for albumin. Protein Eng 
Des Sel. 2006;19(7):291-297. doi: gzl011 [pii]. 
98. Harp KO, Botchway F, Dei-Adomakoh Y, et al. Hemoglobin genotypes modulate 
inflammatory response to Plasmodium infection. Front Immunol. 2020;11:593546. doi: 
10.3389/fimmu.2020.593546 [doi]. 
99. Driss A, Hibbert JM, Wilson NO, Iqbal SA, Adamkiewicz TV, Stiles JK. Genetic 
polymorphisms linked to susceptibility to malaria. Malar J. 2011;10:271-271. doi: 
10.1186/1475-2875-10-271 [doi]. 
100. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health 
burden. Blood. 2010;115(22):4331-4336. doi: 10.1182/blood-2010-01-251348 [doi]. 
101. GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-
adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy 
(HALE) for 195 countries and territories, 1990-2017: A systematic analysis for the global 
burden of disease study 2017. Lancet. 2018;392(10159):1859-1922. doi: S0140-
6736(18)32335-3 [pii]. 
102. WHO. The top 10 causes of death. https://www.who.int/news-room/fact-
sheets/detail/the-top-10-causes-of-
death#:~:text=The%20top%20global%20causes%20of,birth%20asphyxia%20and%20birt
h%20trauma%2C. Updated 2020. Accessed March 11, 2021. 
111 
 
103. ProMED. Undiagnosed pneumonia - china (hubei): Request for information. 
https://promedmail.org/promed-post/?id=6864153%20#COVID19. Updated 2019. 
Accessed March 20, 2021. 
104. WHO. Timeline: WHO's COVID-19 response. 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-
timeline#!. Updated 2021. Accessed March 20, 2021. 
105. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel 
coronavirus in wuhan, china. Lancet. 2020;395(10223):497-506. doi: S0140-
6736(20)30183-5 [pii]. 
106. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new 
coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. doi: 
10.1038/s41586-020-2012-7 [doi]. 
107. Bi S, Qin E, Xu Z, et al. Complete genome sequences of the SARS-CoV: The BJ group 
(isolates BJ01-BJ04). Genomics Proteomics Bioinformatics. 2003;1(3):180-192. doi: 
S1672-0229(03)01023-4 [pii]. 
108. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of 
SARS-CoV-2. Nat Med. 2020;26(4):450-452. doi: 10.1038/s41591-020-0820-9 [doi]. 
112 
 
109. Wacharapluesadee S, Tan CW, Maneeorn P, et al. Evidence for SARS-CoV-2 related 
coronaviruses circulating in bats and pangolins in southeast asia. Nat Commun. 
2021;12(1):972-1. doi: 10.1038/s41467-021-21240-1 [doi]. 
110. Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related 




111. WHO. Novel coronavirus (2019-nCoV) situation report-1. WHO. 2020. 
112. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the 
united states. N Engl J Med. 2020;382(10):929-936. doi: 10.1056/NEJMoa2001191 [doi]. 
113. Basavaraju SV, Patton ME, Grimm K, et al. Serologic testing of U.S. blood donations 
to identify SARS-CoV-2-reactive antibodies: December 2019-january 2020. Clin Infect 
Dis. 2020. doi: 10.1093/cid/ciaa1785 [doi]. 
114. WHO. Novel coronavirus (2019-nCoV) situation report-8. WHO. 2020. 
115. WHO. WHO director-general's remarks at the media briefing on 2019-nCoV on 11 
february 2020. https://www.who.int/director-general/speeches/detail/who-director-
general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. Updated 
2020. Accessed March 20, 2021. 
113 
 
116. WHO. WHO director-general's opening remarks at the media briefing on COVID-19 
- 11 march 2020. https://www.who.int/director-general/speeches/detail/who-director-
general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. 
Updated 2020. Accessed March 20, 2021. 
117. Johns Hopkins University & Medicine. Johns hopkins coronavirus resource center. 
https://coronavirus.jhu.edu/. Updated 2021. Accessed March 20, 2021. 
118. Casadevall A, Scharff MD. Return to the past: The case for antibody-based 
therapies in infectious diseases. Clin Infect Dis. 1995;21(1):150-161. doi: 
10.1093/clinids/21.1.150 [doi]. 
119. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious 
diseases. Nat Rev Microbiol. 2004;2(9):695-703. doi: nrmicro974 [pii]. 
120. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J 
Clin Invest. 2020;130(4):1545-1548. doi: 138003 [pii]. 
121. Casadevall A, Joyner MJ, Pirofski LA. A randomized trial of convalescent plasma for 
COVID-19-potentially hopeful signals. JAMA. 2020;324(5):455-457. doi: 
10.1001/jama.2020.10218 [doi]. 
122. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical 
improvement in patients with severe and life-threatening COVID-19: A randomized 
clinical trial. JAMA. 2020;324(5):460-470. doi: 10.1001/jama.2020.10044 [doi]. 
114 
 
123. Liu Z. Errors in trial of effect of convalescent plasma therapy on time to clinical 
improvement in patients with severe and life-threatening COVID-19. JAMA. 
2020;324(5):518-519. doi: 10.1001/jama.2020.12607 [doi]. 
124. FDA. FDA issues emergency use authorization for convalescent plasma as potential 
promising COVID-19 treatment, another achievement in administration's fight against 
pandemic. https://www.fda.gov/news-events/press-announcements/fda-issues-
emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-
treatment. Updated 2020. Accessed March 21, 2021. 
125. FDA. COVID-19 convalescent plasma EUA decision memo 02052021. . 2021. 
126. Infectious Diseases Society of America, AABB. Clarifying the emergency use 
authorization framework for COVID-19 convalescent plasma: Considerations for 
clinicians. . 2020. 
127. Horby PW, Estcourt L, et al. Convalescent plasma in patients admitted to hospital 




128. Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to 




129. Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent plasma antibody levels and 
the risk of death from covid-19. N Engl J Med. 2021;384(11):1015-1027. doi: 
10.1056/NEJMoa2031893 [doi]. 
130. FDA. Convalescent plasma EUA letter of authorization march 9, 2021. . 2021. 
131. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain 
bound to the ACE2 receptor. Nature. 2020;581(7807):215-220. doi: 10.1038/s41586-
020-2180-5 [doi]. 
132. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in 
the prefusion conformation. Science. 2020;367(6483):1260-1263. doi: 
10.1126/science.abb2507 [doi]. 
133. Benton DJ, Wrobel AG, Xu P, et al. Receptor binding and priming of the spike 
protein of SARS-CoV-2 for membrane fusion. Nature. 2020;588(7837):327-330. doi: 
10.1038/s41586-020-2772-0 [doi]. 
134. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on 
ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 
2020;181(2):271-280.e8. doi: S0092-8674(20)30229-4 [pii]. 
135. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional 




136. Yao H, Song Y, Chen Y, et al. Molecular architecture of the SARS-CoV-2 virus. Cell. 
2020;183(3):730-738.e13. doi: S0092-8674(20)31159-4 [pii]. 
137. Piccoli L, Park YJ, Tortorici MA, et al. Mapping neutralizing and immunodominant 
sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-
resolution serology. Cell. 2020;183(4):1024-1042.e21. doi: S0092-8674(20)31234-4 [pii]. 
138. Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-
CoV-2 spike protein: Potential antivirus drug development for COVID-19. Acta 
Pharmacol Sin. 2020;41(9):1141-1149. doi: 10.1038/s41401-020-0485-4 [doi]. 
139. Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS-
CoV-2 spike protein variants. Elife. 2020;9:10.7554/eLife.61312. doi: 
10.7554/eLife.61312 [doi]. 
140. Kemp SA, Collier DA, Datir RP, et al. SARS-CoV-2 evolution during treatment of 
chronic infection. Nature. 2021. doi: 10.1038/s41586-021-03291-y [doi]. 
141. Resende PC, Bezerra JF, de Vasconcelos, Romero Henrique Teixeira, et al. Spike 
E484K mutation in the first SARS-CoV-2 reinfection case confirmed in brazil, 2020. 
January. 2021;10:2021. 
142. Klein SL, Pekosz A, Park HS, et al. Sex, age, and hospitalization drive antibody 
responses in a COVID-19 convalescent plasma donor population. J Clin Invest. 
2020;130(11):6141-6150. doi: 142004 [pii]. 
117 
 
143. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-
CoV-2 seroconversion in humans. Nat Med. 2020;26(7):1033-1036. doi: 
10.1038/s41591-020-0913-5 [doi]. 
144. Blair PW, Brown DM, Jang M, et al. The clinical course of COVID-19 in the 
outpatient setting: A prospective cohort study. Open Forum Infect Dis. 
2021;8(2):ofab007. doi: 10.1093/ofid/ofab007 [doi]. 
145. Mazumder B, Almond D, Park K, Crimmins EM, Finch CE. Lingering prenatal effects 
of the 1918 influenza pandemic on cardiovascular disease. Journal of Developmental 
Origins of Health and Disease. 2010;1(1):26-34. 
https://www.cambridge.org/core/article/lingering-prenatal-effects-of-the-1918-
influenza-pandemic-on-cardiovascular-disease/26094395058187D6EFDCFCFAF2E584D6. 
Accessed 2021/03/26. doi: 10.1017/S2040174409990031. 
146. Fridman S, Bres Bullrich M, Jimenez-Ruiz A, et al. Stroke risk, phenotypes, and 
death in COVID-19: Systematic review and newly reported cases. Neurology. 
2020;95(24):e3373-e3385. doi: 10.1212/WNL.0000000000010851 [doi]. 
147. Nauen DW, Hooper JE, Stewart CM, Solomon IH. Assessing brain capillaries in 
coronavirus disease 2019. JAMA Neurol. 2021. 




148. Nicola M, Alsafi Z, Sohrabi C, et al. The socio-economic implications of the 




149. FDA. Pfizer-BioNTech COVID-19 vaccine EUA letter of authorization. . 2021. 
150. FDA. Moderna COVID-19 vaccine EUA letter of authorization. . 2021. 
151. FDA. Janssen COVID-19 vaccine EUA letter of authorization. . 2021. 
152. AJMC Staff. A timeline of COVID-19 developments in 2020. 
https://www.ajmc.com/view/a-timeline-of-covid19-developments-in-2020. Updated 
2021. Accessed March 20, 2021. 
153. AJMC Staff. A timeline of COVID-19 vaccine developments in 2021. 
https://www.ajmc.com/view/a-timeline-of-covid-19-vaccine-developments-in-2021. 





Appendix A: Table of Primers 
 
Name Sequence 
pcDNA3.1 Seq. Fwd. 5’GCAGAGCTCTCTGGCTAACTAG3’ 
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